<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        392-212-18
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2018
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        LAGONA 250 mg  Hard capsule
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        TEMOZOLOMIDE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        250
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Capsule, hard
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        5
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Sachet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        3062.1
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="EirGen Pharma" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            EirGen Pharma
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 488]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            SPIMACO
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            SPIMACO ADDWAEIH
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        L01AX03
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Lagona contains a medicine called temozolomide ,This medicine is an antitumour agent.</p><p>Lagona is used for the treatment of patients with specific forms of brain tumours:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; In adults with newly-diagnosed glioblastoma multiforme. Lagona is first used together with radiotherapy (concomitant phase of treatment) and after that alone (monotherapy phase of treatment).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; In children 3 years and older and adult patients with malignant glioma, such as glioblastoma multiforme or anaplastic astrocytoma. Lagona is used in these tumours if they return or get worse after standard treatment.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not take Lagona</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you are allergic (hypersensitive) to temozolomide or any of the other ingredients of Lagona (listed in section 6).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have had an allergic reaction to dacarbazine (an anticancer medicine sometimes called DTIC). Signs of allergic reaction include feeling itchy, breathlessness or wheezing, swelling of the face, lips, tongue or throat.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If certain kinds of blood cells are severely reduced (myelosuppression), such as your white blood cell count and platelet count. These blood cells are important for fighting infection and for proper blood clotting.</p><p>Your doctor will check your blood to make sure you have enough of these cells before you begin treatment.</p><p><strong>Take special care with</strong> <strong>Lagona</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You should be observed closely for the development of a serious form of chest infection called Pneumocystis Jirovecci pneumonia (PCP). If you are a newly-diagnosed patient (glioblastoma multiforme) you may be receiving Lagona for 42 days in combination with radiotherapy.</p><p>In this case, your doctor will also prescribe medicine to help you prevent this type of pneumonia (PCP).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have ever had or might now have a hepatitis B infection. This is because Lagona could cause hepatitis B to become active again, which can be fatal in some cases. Patients will be carefully checked by their doctor for signs of this infection before treatment is started.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have low counts of red blood cells (anaemia), white blood cells and platelets, or blood clotting problems before starting the treatment, or if you develop them during treatment. Your doctor may decide to reduce the dose, interrupt, stop or change your treatment. You may also need other treatments. In some cases, it may be necessary to stop treatment with Lagona. Your blood will be tested frequently during treatment to monitor the side effects of Lagona on your blood cells.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You may have a small risk of other changes in blood cells, including leukaemia.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have nausea (feeling sick in your stomach) and/or vomiting which are very common side effects of Lagona (see section 4 &ldquo;Possible side effects&rdquo;), your doctor may prescribe you a medicine (an anti-emetic) to help prevent vomiting. If you vomit frequently before or during treatment, ask your doctor about the best time to take Lagona until the vomiting is under control. If you vomit after taking your dose, do not take a second dose on the same day.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you develop fever or symptoms of an infection contact your doctor immediately.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not open, crush or chew the capsules. If a capsule is damaged, avoid contact of the powder with your skin, eyes or nose. Avoid inhaling the powder. If you accidentally get some in your eyes or nose, flush the area with water.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you are older than 70 years of age, you might be more prone to infection, bruising or bleeding.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have liver or kidney problems, your dose of Lagona may need to be adjusted.</p><p>Due to lack of experience, Lagona should not be used in children younger than 3 years.</p><p>Lagona may cause permanent infertility. Male patients should use effective contraceptions and not father a child for up to 6 months after stopping treatment. It is recommended to seek advice on conservation of sperm prior to treatment.</p><p><strong>Using other medicines</strong></p><p>Please tell your doctor or pharmacist if you are taking or have recently taken any other medicines, including medicines obtained without a prescription.</p><p><strong>Pregnancy and breast-feeding</strong></p><p>Tell your doctor if you are pregnant, think you might be or are planning to get pregnant. You must not be treated with Lagona during pregnancy unless clearly indicated by your doctor.</p><p>Effective contraceptive precautions must be taken by <strong>both male and female patients </strong>who are taking Lagona (see also &ldquo;Take special care with<strong> </strong>Lagona&rdquo; above). You should stop breast-feeding while receiving treatment<strong> </strong>with Lagona.</p><p><strong>Driving and using machines</strong></p><p>Lagona may make you feel tired or sleepy. In this case, do not drive or use any tools or machines.</p><p><strong>Important information about some of the ingredients of Lagona</strong></p><p>Lagona hard capsules contain lactose. If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicinal product.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Dosage and duration of treatment</p><p>Your doctor will work out your dose of Lagona. This is based on your size (height and weight) and if you have a recurrent tumour and have had chemotherapy treatment in the past.</p><p>You may be given other medicines (anti-emetics) to take before and/or after taking Lagona to prevent or control nausea and vomiting.</p><p><em>Patients with newly-diagnosed glioblastoma multiforme:</em></p><p>If you are a newly-diagnosed patient, treatment will occur in two phases:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Treatment together with radiotherapy (concomitant phase) first,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Followed by treatment with only Lagona (monotherapy phase).</p><p>During the concomitant phase, your doctor will start Lagona at a dose of 75 mg/m2 (usual dose). You will take this dose every day for 42 days (up to 49 days) in combination with radiotherapy. The Lagona dose may be delayed or stopped, depending on your blood counts and how you tolerate your medicine during the concomitant phase. Once the radiotherapy is completed, you will interrupt treatment for 4 weeks. This will give your body a chance to recover. Then, you will start the monotherapy phase.</p><p>During the monotherapy phase, the dose and way you take Lagona will be different. Your doctor will work out your exact dose. There may be up to 6 treatment periods (cycles). Each one lasts 28 days. You will take your new dose of Lagona alone once daily for the first 5 days (&ldquo;dosing days&rdquo;) of each cycle. The first dose will be 150 mg/m2. Then you will have 23 days without Lagona. This adds up to a 28- day treatment cycle. After Day 28, the next cycle will begin. You will again take Lagona once daily for 5 days followed by 23 days without Lagona. The Lagona dose may be adjusted, delayed or stopped depending on your blood counts and how you tolerate your medicine during each treatment cycle.</p><p><em>Patients with tumours that have returned or worsened (malignant glioma, such as glioblastoma multiforme or anaplastic astrocytoma) taking Lagona only:</em></p><p>A treatment cycle with Lagona lasts 28 days. You will take Lagona alone once daily for the first 5 days. This daily dose depends on whether or not you have received chemotherapy before.</p><p>If you have not been previously treated with chemotherapy, your first dose of Lagona will be 200 mg/m2 once daily for the first 5 days. If you have been previously treated with chemotherapy, your first dose of Lagona will be 150 mg/m2 once daily for the first 5 days. Then, you will have 23 days without Lagona. This adds up to a 28-day treatment cycle.</p><p>After Day 28, the next cycle will begin. You will again receive Lagona once daily for 5 days, followed by 23 days without Lagona.</p><p>Before each new treatment cycle, your blood will be tested to see if the Lagona dose needs to be adjusted. Depending on your blood test results, your doctor may adjust your dose for the next cycle.</p><p><strong>How to take Lagona</strong></p><p>Take your prescribed dose of Lagona once a day, preferably at the same time each day.</p><p>Take the capsules on an empty stomach; for example, at least one hour before you plan to eat breakfast. Swallow the capsule(s) whole with a glass of water. Do not open or chew the capsules. If a capsule is damaged, avoid contact with your skin, eyes or nose. If it occurs, wash the affected area thoroughly.</p><p>Depending on the prescribed dose, you may have to take more than one capsule together, eventually with different strengths (content of active substance, in mg). The colour of the capsule cap is different for each strength (see in the table below).</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p>Strength</p></td><td><p>Colour of the cap</p></td></tr><tr><td><p>Lagona 5 mg hard capsules</p></td><td><p>Green</p></td></tr><tr><td><p>Lagona 20 mg hard capsules</p></td><td><p>Orange</p></td></tr><tr><td><p>Lagona 100 mg hard capsules</p></td><td><p>Purple</p></td></tr><tr><td><p>Lagona 140 mg hard capsules</p></td><td><p>Blue</p></td></tr><tr><td><p>Lagona 180 mg hard capsules</p></td><td><p>Chocolate brown</p></td></tr><tr><td><p>Lagona 250 mg hard capsules</p></td><td><p>White</p></td></tr></tbody></table><p>&nbsp;</p><p>You should make sure you fully understand and remember the following:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; How many capsules you need to take every dosing day. Ask your doctor or pharmacist to write it down (including the colour).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Which days are your dosing days.</p><p>Review the dose with your doctor each time you start a new cycle, since it may be different from the last cycle.</p><p>Always take Lagona exactly as your doctor has told you. It is very important to check with your doctor or pharmacist if you are not sure. Errors in how you take this medicine may have serious health consequences.</p><p><strong>If you take more Lagona than you should</strong></p><p>If you accidentally take more Lagona capsules than you were told to, contact your doctor or pharmacist immediately.</p><p><strong>If you forget to take Lagona</strong></p><p>Take the missed dose as soon as possible during the same day. If a full day has gone by, check with your doctor. Do not take a double dose to make up for a forgotten dose, unless your doctor tells you to do so.</p><p>If you have any further questions on the use of this product, ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, Lagona can cause side effects, although not everybody gets them.</p><p>Contact your doctor <strong>immediately </strong>if you have any of the following:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; A severe allergic (hypersensitive) reaction (hives, wheezing or other breathing difficulty),</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Uncontrolled bleeding,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Seizures (convulsions),</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Fever,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; A severe headache that does not go away.</p><p>Lagona treatment can cause a reduction in certain kinds of blood cells.</p><p>This may cause you to have increased bruising or bleeding, anaemia (a shortage of red blood cells), fever, and reduced resistance to infections. The reduction in blood cell counts is usually short-lived. In some cases, it may be prolonged and may lead to a very severe form of anaemia (aplastic anaemia). Your doctor will monitor your blood regularly for any changes, and will decide if any specific treatment is needed. In some cases, your Lagona dose will be reduced or treatment stopped.</p><p>Side effects from clinical studies:</p><p>Side effects may occur with certain frequencies, which are defined as follows:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Very common: may affect more than 1 in 10 people</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Common: may affect up to 1 in 10 people</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Uncommon: may affect up to 1 in 100 people</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Rare: may affect up to 1 in 1,000 people</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Very rare: may affect up to 1 in 10,000 people</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Not known: frequency cannot be estimated from the available data.</p><p><em>Lagona</em> <em>in combination treatment with radiotherapy in newly-diagnosed glioblastoma</em></p><p>Patients receiving Lagona in combination with radiotherapy may experience different side effects than patients taking Lagona alone. The following side effects may occur, and may require medical attention.</p><p><strong>Very common: </strong>loss of appetite, headache, constipation, nausea (feeling sick in your stomach), vomiting, rash, hair loss, tiredness.</p><p><strong>Common: </strong>oral infections, wound infection, reduced number of blood cells (neutropenia, thrombocytopenia, lymphopenia, leukopenia), increased sugar in the blood, loss of weight, change in mental status or alertness, anxiety/depression, sleepiness, difficulty speaking, impaired balance, dizziness, confusion, forgetfulness, difficulty concentrating, inability to fall asleep or stay asleep, tingling sensation, bruising, shaking, abnormal or blurry vision, double vision, hearing impairment, shortness of breath, cough, blood clot in the legs, fluid retention, swollen legs, diarrhoea, stomach or abdominal pain, heartburn, upset stomach, difficulty swallowing, dry mouth, skin irritation or redness, dry skin, itching, muscle weakness, painful joints, muscle aches and pains, frequent urination, difficulty with holding your urine, allergic reaction, fever, radiation injury, face swelling, pain, abnormal taste, abnormal liver function tests.</p><p><strong>Uncommon: </strong>flu-like symptoms, red spots under the skin, low potassium level in the blood, weight gain, mood swings, hallucination and memory impairment, partial paralysis, impaired coordination, impaired sensations, partial loss of vision, dry or painful eyes, deafness, infection of the middle ear, ringing in the ears, earache, palpitations (when you can feel your heart beat), blood clot in the lung, high blood pressure, pneumonia, inflammation of your sinuses, bronchitis, a cold or the flu, swollen stomach, difficulty controlling your bowel movements, haemorrhoids, peeling skin, increased skin sensitivity to sunlight, change in skin colour, increased sweating, muscle damage, back pain, difficulty in urinating, vaginal bleeding, sexual impotence, absent or heavy menstrual periods, vaginal irritation, breast pain, hot flushes, shivering, discolouration of your tongue, change in your sense of smell, thirst, tooth disorder.</p><p><em>Lagona</em> <em>monotherapy in recurrent or progressive glioma</em></p><p>The following side effects may occur, and may require medical attention.</p><p><strong>Very common: </strong>reduced number of blood cells (neutropenia or lymphopenia, thrombocytopenia), loss of appetite, headache, vomiting, nausea (feeling sick in your stomach), constipation, tiredness.</p><p><strong>Common: </strong>loss of weight, sleepiness, dizziness, tingling sensation, shortness of breath, diarrhoea, abdominal pain, upset stomach, rash, itching, hair loss, fever, weakness, shivering, feeling unwell, pain, change in taste.</p><p><strong>Uncommon: </strong>reduced number of blood cell counts (pancytopenia, anaemia, leukopenia).</p><p><strong>Rare: </strong>cough, infections including pneumonia.</p><p><strong>Very rare: </strong>skin redness, urticaria (hives), skin eruption, allergic reactions.</p><p>Other side effects:</p><p>&nbsp;</p><p>Cases of elevations of liver enzymes have been commonly reported. Cases of increased bilirubin, problems with bile flow (cholestasis), hepatitis and injury to the liver, including fatal liver failure, have been uncommonly reported.</p><p>Very rare cases of severe rash with skin swelling, including on the palms of the hands and soles of the feet, or painful reddening of the skin and/or blisters on the body or in the mouth have been observed. Tell your doctor <strong>immediately </strong>if this occurs.</p><p>Very rare cases of lung side effects have been observed with Lagona.</p><p>Patients usually present with shortness of breath and cough. Tell your doctor if you notice any of these symptoms.</p><p>In very rare cases, patients taking Lagona and medicines like it may have a small risk of developing secondary cancers, including leukaemia.</p><p>&nbsp;</p><p>New or reactivated (recurring) cytomegalovirus infections and reactivated hepatitis B virus infections have been uncommonly reported. Cases of brain infections caused by herpes virus (meningoencephalitis herpetic), including fatal cases, have been uncommonly reported.</p><p>Cases of diabetes insipidus have been uncommonly reported. Symptoms of diabetes insipidus include passing a lot of urine and feeling thirsty.</p><p>&nbsp;</p><p>&nbsp;</p><p>If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep out of the reach and sight of children.</p><p>Do not use Lagona after the expiry date which is stated on the label and carton. The expiry date refers to the last day of that month.</p><p>HDPE Bottle presentation:</p><p>Store below 30 &deg;C.</p><p>Store in the original bottle in order to protect from moisture.</p><p>Keep the bottle tightly closed.</p><p>Sachet presentation</p><p>Store below 30 &deg;C.</p><p>Medicines should not be disposed via wastewater or household waste. Ask you pharmacist how to dispose of medicines no longer required. These measures will help to protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The active substance is temozolomide.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Lagona 5 mg hard capsules: each capsule contains 5 mg temozolomide.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Lagona 20 mg hard capsules: each capsule contains 20 mg temozolomide.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Lagona 100 mg hard capsules: each capsule contains 100 mg temozolomide.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Lagona 140 mg hard capsules: each capsule contains 140 mg temozolomide.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Lagona 180 mg hard capsules: each capsule contains 180 mg temozolomide.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Lagona 250 mg hard capsules: each capsule contains 250 mg temozolomide.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The other ingredients are:</p><p>Capsule content</p><p>Lactose Anhydrous,</p><p>Colloidal silicon dioxide,</p><p>Sodium Starch Glycollate (Type A),</p><p>Tartaric Acid,</p><p>Stearic Acid,</p><p>Capsule shell, Size 0:</p><p>Lagona 5 mg hard capsules: gelatin, titanium dioxide (E 171). Yellow iron oxide (E 172), red iron oxide (E 172).</p><p>Lagona 20 mg hard capsules: gelatin, titanium dioxide (E 171), red iron oxide (E 172), yellow iron oxide (E 172).</p><p>Lagona 100 mg hard capsules: gelatin, titanium dioxide (E 171), indigotine FD&amp;C blue2 (E 132).</p><p>Lagona 140 mg hard capsules: Gelatin, titanium dioxide (E 171), indigotine FD&amp;C blue 2 (E 132).</p><p>Lagona 180 mg hard capsules: Gelatin, titanium dioxide (E 171), yellow iron oxide (E 172), red iron oxide (E 172), black iron oxide (E 172).</p><p>Lagona 250 mg hard capsules: gelatin, titanium dioxide (E 171).</p><p>Printing ink</p><p>Shellac, dehydrated alcohol, Isopropyl alcohol, Butyl alcohol, propylene glycol, purified water, sodium ammonia solution, potassium hydroxide, black iron oxide (E 172).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Lagona 5 mg hard capsules: Hard gelatin capsules size 0 (green opaque cap/white opaque body) with 5 printed on the body.
Lagona 20 mg hard capsules: Hard gelatin capsules size 0 (orange opaque cap /white opaque body) with 20 printed on the body.
Lagona 100 mg hard capsules: Hard gelatin capsules size 0 (purple opaque cap /white opaque body) with 100 printed on the body.
Lagona 140 mg hard capsules: Hard gelatin capsules size 0 (blue opaque cap /white opaque body) with 140 printed on the body.
Lagona 180 mg hard capsules: Hard gelatin capsules size 0 (chocolate brown opaque cap /white opaque body) with 180 printed on the body.
Lagona 250 mg hard capsules: Hard gelatin capsules size 0 (white opaque cap /white opaque body) with 250 printed on the body.
HDPE Bottle presentation:
White opaque High Density Polyethylene Bottles with Polypropylene push lock assembly closure, with polyester coil containing 5 capsules.
Sachet presentation
Sachets composed of paper on linear low density polyethylene (outermost layer), aluminium and ethylene acrylic acid co-polymer (innermost layer). Each sachet contains 1 hard capsule and is dispensed in a cardboard carton. The carton contains 5 or 20 hard capsules, individually sealed in sachets.
Not all pack sizes may be marketed.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Manufactured by: </strong></p><p><strong>EirGen Pharma Ltd.</strong></p><p><strong>For: SPIMACO</strong></p><p>AlQassim pharmaceutical plant</p><p>Saudi Pharmaceutical Industries &amp;</p><p>Medical Appliance Corporation</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                November 2017.
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p>لاجونا يحتوي على المادة الفعالة تيموزولومايد و هو دواء مضاد للورم.</p><p>يستخدم لاجونا لعلاج المرضى الذين يعانون من أشكال محددة من أورام المخ:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الورم الأرومي الدبقي متعدد الأشكال المشخص حديثاً في البالغين. فى البداية يستخدم لاجونا جنباً إلى جنب مع العلاج الإشعاعي (فى مرحلة الاقتران مع العلاج الإشعاعى) وبعد ذلك يستخدم لاجونا وحده كعلاج (فى مرحلة العلاج الواحد).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الورم الخبيث في الأطفال من سن 3 سنين والبالغين, مثل الورم الأرومي الدبقي متعدد الأشكال أو الورم النجمي الكشمي الخبيث. يستخدم لاجونا في هذه الأورام فى حالة عودتها مرة أخرى أو ازدياد سوء الحالة بعد استخدام العلاج المعتاد.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>لا تقم بتناول لاجونا فى الحالات الآتية:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعانى من فرط التحسس تجاه مادة تيموزولومايد أو تجاه أى من المكونات الأخرى فى لاجونا (المدرجة في الفقرة 6).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا تعرضت مسبقاً لتفاعل تحسسى تجاه داكاربازين (وهو دواء مضاد للسرطان ويعرف أحياناً باسم DTIC). وتشمل علامات الحساسية الشعور بالحكة, أو ضيق في التنفس أو أزيز, أو تورم في الوجه والشفتين واللسان أو الحلق.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فى حالة حدوث نقص حاد فى بعض أنواع خلايا الدم (كبت نقي العظم), مثل خلايا الدم البيضاء والصفائح الدموية. هذه الخلايا تلعب دوراً هاماً فى مكافحة العدوى وتخثر الدم بشكل سليم.</p><p>قد يقوم الطبيب المعالج بفحص الدم لديك للتأكد من وجود عدد كافِ من هذه الخلايا قبل أن تبدأ العلاج.</p><p>&nbsp;</p><p><strong>ينبغى توخى الحذر مع لاجونا</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يجب أن تخضع للملاحظة بشكل وثيق لمراقبة تطور حالة خطيرة من الالتهاب الرئوى تعرف باسم التهاب رئوي بالمتكيسة الجؤجؤية. إذا كنت مريض مشخص حديثاُ بأنك تعانى من ورم أرومي دبقي متعدد الأشكال<strong> </strong>فقد تحتاج إلى العلاج بواسطة لاجونا مع العلاج الإشعاعى لمدة 42 يوماً. فى هذه الحالة سيلجأ طبيبك المعالج إلى وصف دواء لمنع حدوث هذه الحالة من الالتهاب الرئوى.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان لديك حاليا أو سابقا أو لديك احتمالية الإصابة بفيروس الالتهاب الكبدي الوبائي<strong> </strong>بي، وذلك لأن هناك احتمالية أن يساعد لاجونا على تنشيط فيروس بي والذي يمكن أن يؤدي للوفاة في بعض الحالات. ولذلك ينبغي على المرضي أن يراقبوا بعناية من قبل الأطباء لملاحظة أي أعراض لهذا الفيروس قبل البدء في العلاج.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;إذا كان لديك نقص فى عدد خلايا الدم الحمراء (فقر الدم), وخلايا الدم البيضاء والصفائح الدموية, أو لديك مشاكل فى تخثر الدم قبل البدء فى العلاج, أو فى حالة تعرضك لأى من تلك الأعراض أثناء العلاج. فقد يقرر طبيبك المعالج خفض الجرعة أو إيقاف العلاج أو تغيير العلاج الخاص بك. قد تحتاج أيضاً إلى علاجات أخرى. فى بعض الحالات, قد يكون من الضرورى إيقاف العلاج بواسطة لاجونا. سوف يتم فحص الدم لديك بصورة منتظمة أثناء العلاج بواسطة لاجونا لرصد الأعراض الجانبية لدواء لاجونا على خلايا الدم لديك.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قد يكون لديك خطر صغير من تغيرات أخرى في خلايا الدم, بما في ذلك سرطان الدم.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان لديك غثيان (الشعور بالغثيان في المعدة) و / أو تقيؤ وهي من الأعراض الجانبية الشائعة جداً لدواء لاجونا (انظر القسم 4 &quot;الأعراض الجانبية المحتملة&quot;), فإن طبيبك قد يصف لك دواء (مضاد للقيء) للمساعدة في منع التقيؤ. إذا كنت تتقيأ كثيراً قبل أو أثناء العلاج, اسأل طبيبك عن أفضل وقت لتناول لاجونا حتى يكون التقيؤ تحت السيطرة. إذا تعرضت للتقيؤ بعد تناول الجرعة, لا تأخذ جرعة ثانية في نفس اليوم.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا أُصبت بحمى أو أعراض عدوى اتصل بطبيبك على الفور.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تقم بفتح أو سحق أو مضغ الكبسولات. فى حالة تلف الكبسولة, تجنب تعرض الجلد أو العينين أو الأنف للمسحوق داخل الكبسولة. تجنب استنشاق المسحوق. فى حالة التعرض عن طريق الخطأ للمسحوق من خلال عينيك أو أنفك, قم بغسل الجزء المتعرض للمسحوق بالماء.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان عمرك أكثر من 70 عاماً فقد تكون أكثر عرضة لحدوث عدوى أو كدمات أو نزف.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعانى من مشاكل بالكبد أو الكلى, فقد تحتاج إلى تعديل الجرعة الخاصة بك من لاجونا.</p><p>نظراً لانحسار الخبرة, يجب عدم استخدام لاجونا فى حالة الأطفال الأقل فى العمر من 3 سنوات. لاجونا قد يسبب العقم الدائم. وينبغي على المرضى من الذكور الاستخدام الفعال لوسائل منع الحمل والحرص على عدم إنجاب طفل لمدة تصل إلى 6 أشهر بعد وقف العلاج. ومن الموصى به طلب المشورة بشأن الحفاظ على الحيوانات المنوية قبل العلاج.</p><p><strong>تناول أدوية أخرى</strong></p><p>فضلاً أخبر طبيبك المعالج أو الصيدلى بشأن أى أدوية أخرى تتناولها حالياً أو تناولتها مؤخراً بما فيها تلك التى حصلت عليها بدون وصفة طبية.</p><p><strong>الحمل والرضاعة الطبيعية</strong></p><p>أخبرى طبيبك المعالج إذا كنتِ حاملاً أو تعتقدين بأنكِ حامل أو تخططين للحمل. حيث يجب عدم استخدام لاجونا أثناء الحمل إلا إذا أوصى الطبيب المعالج بخلاف ذلك بشكل واضح. يجب اتخاذ الاحتياطات اللازمة لمنع الحمل للمرضى من الذكور والإناث الخاضعين للعلاج بواسطة لاجونا (انظر أيضاً فقرة &quot; ينبغى توخى الحذر مع لاجونا&quot; أعلاه). يجب التوقف عن الإرضاع الطبيعى أثناء العلاج بلاجونا.</p><p>&nbsp;</p><p><strong>القيادة واستخدام الآلات</strong></p><p>قد يشعرك لاجونا بالتعب أو النعاس. فى هذه الحالة, لا تقم بقيادة السيارة أو استخدام أى أدوات أو آلات.</p><p><strong>معلومات هامة حول بعض مكونات لاجونا</strong></p><p>كبسولات لاجونا الصلبة تحتوى على لاكتوز. إذا تم إبلاغك من قبل طبيبك المعالج بعدم تحملك لبعض أنواع السكريات, تواصل مع طبيبك المعالج قبل البدء فى تناول هذا الدواء.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>الجرعة ومدة العلاج</p><p>سوف يحدد طبيبك المعالج الجرعة الخاصة بك اعتماداً على أبعاد جسمك (الطول والوزن) واستناداً على ما إذا كان لديك ورم متكرر, أو خضعت للعلاج الكيماوي مسبقاً.</p><p>قد يصف لك الطبيب أدوية أخرى مضادة للقئ أو الغثيان لتناولها قبل و/أو بعد لاجونا للحد من أو السيطرة على الغثيان والتقيؤ.</p><p>المرضى المشخصين حديثاُ بالإصابة بالورم الأرومي الدبقي متعدد الأشكال:</p><p>إذا كنت من المرضى المشخصين حديثاُ بالإصابة بهذا المرض, سوف يتشكل العلاج الخاص بك على مرحلتين:</p><ul><li>فى البداية يستخدم لاجونا جنباً إلى جنب مع العلاج الإشعاعي (مرحلة الاقتران مع العلاج الإشعاعى),</li><li>وبعد ذلك يستخدم لاجونا وحده كعلاج (مرحلة العلاج الواحد).</li></ul><p>أثناء مرحلة الاقتران مع العلاج الإشعاعى, سوف يبدأ لك طبيبك المعالج بجرعة من لاجونا وهى 75 ملجم/م2 (الجرعة المعتادة).</p><p>سوف تقوم بتناول هذه الجرعة يومياً لمدة 42 يوماً (وقد تصل إلى 49 يوماً) جنباً إلى جنب مع العلاج الإشعاعى.</p><p>قد يتم تأجيل أو إيقاف الجرعة من لاجونا اعتماداً على عدد خلايا الدم الخاص بك ومدى تحملك للدواء أثناء مرحلة الاقتران. بمجرد إتمام العلاج الإشعاعى, سوف تقوم بالانقطاع عن العلاج لمدة 4 أسابيع. مما يعطى الفرصة لجسمك ليتعافى. بعد ذلك, سوف تبدأ مرحلة العلاج الواحد.</p><p>أثناء مرحلة العلاج الواحد, ستكون طريقة العلاج والجرعة الخاصة بكبسولات لاجونا مختلفة. سوف يحدد لك الطبيب المعالج الجرعة الخاصة بك بالضبط. والتى قد تتشكل مما قد يصل إلى 6 دورات من العلاج. تستمر كل منها لمدة 28 يوماً. سوف تقوم بتناول الجرعة الجديدة الخاصة بك من لاجونا وحده مرة واحدة يومياً لمدة الخمسة أيام الأولى (&quot;أيام الجرعات&quot;) من كل دورة. ستكون الجرعة الأولى 150 ملجم/م2. بعد ذلك, ستتوقف عن لاجونا لمدة 23 يوماً. وبذلك تكون دورة العلاج الواحدة تتكون من 28 يوماً. بعد اليوم الثامن والعشرون, ستبدأ الدورة التالية. سوف تقوم بتناول لاجونا مرة أخرى بجرعة 150 ملجم/م2 مرة واحدة يومياً لمدة 5 أيام ثم تتوقف عن تناول لاجونا لمدة 23 يوماً. قد يتم ضبط أو تأجيل أو إيقاف الجرعة من لاجونا اعتماداً على عدد خلايا الدم الخاص بك ومدى تحملك للدواء أثناء كل دورة علاج.</p><p>&nbsp;</p><p>المرضى الذين يعانون من الأورام التي عادت أو ساءت (الورم الخبيث, مثل الورم الأرومي الدبقي متعدد الأشكال أو الورم النجمي الكشمي الخبيث) يتشكل العلاج من لاجونا فقط:</p><p>دورة العلاج مع لاجونا تستمر 28 يوماً. سوف تتناول لاجونا وحده مرة واحدة يومياً لمدة 5 أيام الأولى. هذه الجرعة اليومية تعتمد على ما إذا كنت قد تلقيت العلاج الكيميائي من قبل أم لا.</p><p>إذا لم تكن قد تمت معالجتك سابقاً بالعلاج الكيميائي, ستكون الجرعة الأولى من لاجونا الخاصة بك 200 ملجم / م2 مرة واحدة يوميا لمدة 5 أيام الأولى. إذا كنت قد تمت معالجتك مسبقاً بالعلاج الكيميائي, ستكون الجرعة الأولى من لاجونا الخاصة بك 150 ملجم / م2 مرة واحدة يومياً لمدة 5 أيام الأولى. ثم, تتوقف عن تناول لاجونا لمدة 23 يوماً. وهذا يجعل دورة العلاج تصل إلى 28 يوماً.</p><p>بعد اليوم الثامن والعشرون, ستبدأ الدورة التالية. سوف تقوم مرة أخرى بتناول لاجونا مرة واحدة يومياً لمدة 5 أيام ثم تتوقف عن تناول لاجونا لمدة 23 يوماً.</p><p>قبل كل دورة علاج جديدة, سيتم اختبار الدم لديك لمعرفة ما إذا كانت جرعة لاجونا تحتاج إلى تعديل. اعتماداً على نتائج اختبار الدم الخاص بك, فإن طبيبك قد يقوم بضبط الجرعة للدورة المقبلة.</p><p><strong>كيفية تناول لاجونا</strong></p><p>قم بتناول الجرعة الموصوفة لك من لاجونا مرة واحدة يومياً ويفضل في نفس الوقت من كل يوم.</p><p>قم بتناول الكبسولات على معدة فارغة. على سبيل المثال, ساعة واحدة على الأقل قبل الوقت المحدد لتناول وجبة الفطور. قم بابتلاع الكبسولة (أو الكبسولات) مع كوب من الماء. لا تقم بفتح أو مضغ الكبسولات. في حالة تلف الكبسولة, تجنب ملامسة الجلد والعينين أو الأنف. إذا حدث ذلك, اغسل المنطقة المصابة بدقة.</p><p>اعتماداً على الجرعة الموصوفة, قد تضطر إلى تناول أكثر من كبسولة واحدة فى آن واحد, وقد تكون بتركيزات مختلفة (محتوى المادة الفعالة بوحدة الملجم). لون غطاء الكبسولة مختلف فى كل تركيز (انظر الجدول أدناه).</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p>التركيز</p></td><td><p>لون غطاء الكبسولة</p></td></tr><tr><td><p>لاجونا 5 ملجم كبسولات صلبة</p></td><td><p>أخضر</p></td></tr><tr><td><p>لاجونا 20 ملجم كبسولات صلبة</p></td><td><p>برتقالى</p></td></tr><tr><td><p>لاجونا 100 ملجم كبسولات صلبة</p></td><td><p>بنفسجى</p></td></tr><tr><td><p>لاجونا 140 ملجم كبسولات صلبة</p></td><td><p>أزرق</p></td></tr><tr><td><p>لاجونا 180 ملجم كبسولات صلبة</p></td><td><p>بنى شوكولاتة</p></td></tr><tr><td><p>لاجونا 250 ملجم كبسولات صلبة</p></td><td><p>أبيض</p></td></tr></tbody></table><p>&nbsp;</p><p>يجب عليك أن تتأكد من فهمك التام وتذكرك لما يلى:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كم عدد الكبسولات التى تحتاج إلى أن تتناولها كل يوم من أيام الجرعات. اسأل طبيبك المعالج أو الصيدلي ليقوم بكتابتها لك (بما في ذلك لون غطاء الكبسولة).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ما هي الأيام التى تمثل أيام الجرعات.</p><p>قم بمراجعة الجرعة مع الطبيب في كل مرة تبدأ دورة علاج جديدة, لأنها قد تكون مختلفة عن الدورة الماضية.</p><p>قم دائماً بتناول لاجونا تماماً كما أخبرك طبيبك المعالج. من المهم جداً أن تتحقق من خلال طبيبك المعالج أو الصيدلي إذا لم تكن متأكداً. الأخطاء في كيفية تناول هذا الدواء قد تسبب عواقب صحية خطيرة.</p><p>&nbsp;</p><p><strong>فى حالة تناول لاجونا أكثر مما ينبغى</strong></p><p>فى حالة تناول لاجونا عن طريق الخطأ بجرعة أكبر من تلك الموصوفة لك, تواصل مع طبيبك المعالج أو الصيدلى فى الحال.</p><p><strong>فى حالة نسيان تناول الجرعة الخاصة بك من لاجونا</strong></p><p>قم بتناول الجرعة المنسية في أقرب وقت ممكن خلال نفس اليوم. إذا مر يوم كامل, قم بمراجعة الطبيب. لا تتناول جرعة مضاعفة لتعويض الجرعة المنسية, ما لم يخبرك طبيبك المعالج بذلك.</p><p>إذا كانت لديك أي أسئلة أخرى عن استخدام هذا الدواء, اسأل طبيبك المعالج أو الصيدلي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>مثل جميع الأدوية, قد يسبب لاجونا أعراضاً جانبية وإن لم تكن تحدث لكل من يتناول هذا الدواء.</p><p>اتصل بطبيبك على الفور إذا كان لديك أي من الأعراض التالية:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تفاعلات تحسسية شديدة (الشرى, والصفير عند التنفس أو غيرها من صعوبة في التنفس),</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نزيف خارج السيطرة,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نوبات (تشنجات),</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حمى,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صداع شديد مستمر.</p><p>العلاج باستخدام لاجونا قد يسبب انخفاضاً في أنواع معينة من خلايا الدم.</p><p>وهذا قد يسبب لك زيادة فى احتمالية حدوث كدمات أو نزيف, أو فقر الدم (نقص في خلايا الدم الحمراء), أو حمى, أو نقص فى مقاومة العدوى. انخفاض عدد خلايا الدم عادةً ما يكون قصير الأجل. في بعض الحالات, قد يكون لفترات طويلة وربما يؤدي إلى نوع حاد جداً من فقر الدم (فقر الدم اللاتنسجي). سيقوم الطبيب بمراقبة دمك بانتظام لرصد أي تغييرات, وسوف يقرر إذا كانت هناك حاجة إلى أي علاج محدد. في بعض الحالات, سيتم خفض جرعة لاجونا أو توقف العلاج.</p><p>الأعراض الجانبية من الدراسات السريرية:</p><p>قد تحدث أعراض جانبية بمعدلات معينة, والتي تعرف كما يلي:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; شائعة جداً: والتى تؤثر على أكثر من 1 لكل 10 مستخدمين لهذا الدواء.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; شائعة: والتي قد تؤثر على ما يصل إلى 1 في كل 10 مستخدم لهذا الدواء.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; غير شائعة: والتي قد تؤثر على ما يصل إلى 1 في كل 100 مستخدم لهذا الدواء.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نادرة: والتي قد تؤثر على ما يصل إلى 1 في كل 1000 مستخدم لهذا الدواء.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نادرة جداً: والتي قد تؤثر على ما يصل إلى 1 في كل 10000 مستخدم لهذا الدواء.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; غير معروفة: والتى لا يمكن أن يستدل علي معدلها من خلال المعلومات المتاحة.</p><p><em>فى حالة استخدام لاجونا بالاقتران مع العلاج الإشعاعى للمرضى المشخصين حديثاُ بالإصابة بالورم الأرومي الدبقي</em></p><p>قد تختلف الأعراض الجانبية لدى المرضى الخاضعين للعلاج عن طريق اقتران لاجونا مع العلاج الإشعاعى عن المرضى الخاضعين للعلاج عن طريق لاجونا وحده. الأعراض الجانبية التالية قد تحدث, وقد تتطلب عناية طبية.</p><p><strong>أعراض جانبية شائعة جداً:</strong> فقدان الشهية وصداع وإمساك, غثيان (الشعور بالغثيان في المعدة), وتقيؤ, وطفح جلدي, وفقدان الشعر, وتعب.</p><p><strong>أعراض جانبية شائعة:</strong> التهابات الفم والتهاب الجروح, وانخفاض عدد خلايا الدم (نقص العدلات, قلة الصفيحات, نقص اللمفاويات, نقص الكريات البيض), وزيادة نسبة السكر في الدم, وفقدان الوزن, وتغير في الحالة العقلية أوالتركيز, قلق/اكتئاب, نعاس, وصعوبة في الكلام, وضعف التوازن, دوخة, ارتباك, نسيان, صعوبة التركيز وعدم القدرة على النوم أو البقاء نائماً, الإحساس بالوخز, كدمات, اهتزاز, خلل أو ضبابية فى الرؤية, ازدواج بالرؤية, ضعف وضيق في التنفس, سعال, وتجلط الدم في الساقين, تراكم السوائل, تورم الساقين, إسهال, آلام في البطن أو المعدة, حرقة فى المعدة, واضطراب في المعدة وصعوبة في البلع, جفاف الفم, تهيج أو احمرار الجلد, جفاف الجلد, حكة, ضعف العضلات وألم بالمفاصل, وآلام في العضلات, كثرة التبول, صعوبة في عقد البول, حساسية, حمى, جروح من الإشعاع, تورم الوجه, ألم, خلل فى التذوق, خلل فى اختبارات وظائف الكبد.</p><p><strong>أعراض جانبية غير شائعة:</strong> أعراض تشبه الأنفلونزا, بقع حمراء تحت الجلد، وانخفاض مستوى البوتاسيوم في الدم، وزيادة الوزن، وتقلبات المزاج، هلوسة وضعف الذاكرة، شلل جزئي، ضعف التنسيق، ضعف فى الإحساس، فقدان جزئي للرؤية، جفاف أو ألم بالعيون، صمم، التهاب الأذن الوسطى، طنين في الأذنين، وجع الأذن، خفقان (عندما يمكنك أن تشعر بنبض قلبك)، تجلط الدم في الرئة, ارتفاع ضغط الدم، التهاب رئوي، التهاب الجيوب الأنفية، التهاب القصبات الهوائية، برد أو أنفلونزا، انتفاخ المعدة، صعوبة في السيطرة على حركة الأمعاء، بواسير، تقشير البشرة، وزيادة حساسية الجلد لآشعة الشمس، وتغير في لون الجلد، وزيادة التعرق، وتلف العضلات، وآلام الظهر، وصعوبة في التبول، نزيف مهبلي، عجز جنسي، غياب أو ثقل فى فترات الطمث، تهيج المهبل، ألم الثدي، هبات ساخنة، ارتعاش، تغير لون اللسان، تغير في حاسة الشم, عطش, اضطرابات الأسنان.</p><p><em>فى حالة استخدام لاجونا وحده لعلاج الأورام المتكررة أو التقدمية:</em></p><p>الأعراض الجانبية التالية قد تحدث, وقد تتطلب عناية طبية<em>.</em></p><p><strong>أعراض جانبية شائعة جداً:</strong> انخفاض عدد خلايا الدم (نقص العدلات, أو نقص اللمفاويات, أو قلة الصفيحات), فقدان الشهية, صداع, تقيؤ, غثيان (شعور بالغثيان فى المعدة), إمساك , تعب<em>.</em></p><p><strong>أعراض جانبية شائعة:</strong><em> </em>&nbsp;نقص الوزن, نعاس, دوخة, إحساس بالوخز, ضيق التنفس, إسهال, ألم بالبطن, اضطراب في المعدة, طفح جلدي، حكة، فقدان الشعر، حمى، ضعف، ارتعاش، شعور بتوعك أو ألم، تغير في حاسة التذوق.</p><p><strong>أعراض جانبية غير شائعة:</strong>&nbsp; انخفاض عدد خلايا الدم (قلة الكريات الشاملة، وفقر الدم، نقص الكريات البيض).</p><p><strong>أعراض جانبية نادرة: </strong>سعال, عدوى وتشمل الالتهاب الرئوى.</p><p><strong>أعراض جانبية نادرة جداً:</strong> احمرار الجلد, أرتيكاريا (الشرى), طفح جلدي, تفاعلات تحسسية.</p><p><strong>أعراض جانبية أخرى:</strong></p><p>وقد تم الإبلاغ عن حالات ارتفاعات انزيمات الكبد بشكل شائع. وقد تم الإبلاغ عن حالات زيادة البيليروبين، ومشاكل مع تدفق الصفراء (ركود صفراوي) والتهاب الكبد وإصابة الكبد، بما في ذلك فشل الكبد القاتل، بشكل غير شائع.</p><p>قد تمت ملاحظة بعض الحالات النادرة من الطفح الجلدى الشديد مع تورم الجلد, بما فيه راحتى اليدين وباطن القدمين, أو احمرار مؤلم بالجلد و/أو تقرحات بالجسم أو بالفم. أخبر طبيبك المعالج فوراً حال حدوث أى من تلك الأعراض.</p><p>قد تمت ملاحظة أعراض جانبية مرتبطة بالرئة فى حالات نادرة جداً مع استخدام لاجونا.</p><p>عادةً تتمثل فى تعرض المرضى لضيق التنفس والسعال. أخبر طبيبك المعالج إذا لاحظت أياً من تلك الأعراض.</p><p>فى حالات نادرة جداً, عند استخدام المرضى لعقار لاجونا أو الأدوية المشابهة قد يتعرض هؤلاء المرضى لخطر الإصابة بسرطانات ثانوية وتشمل سرطان الدم.</p><p>تم الإبلاغ عن إصابات جديدة أو إعادة تنشيط (تكرار) الفيروس المضخم للخلايا و تنشيط فيروس التهاب الكبد بي بشكل غير شائع. وقد تم الإبلاغ عن حالات إصابات الدماغ الناجمة عن فيروس الهربس (التهاب السحايا والدماغ)، بما في ذلك الحالات القاتلة بشكل غير شائع.</p><p>وقد تم الإبلاغ عن الإصابة بحالات مرض السكري الكاذب بشكل غير شائع. وتشمل أعراضه كثرة التبول والشعور بالعطش.</p><p>إذا أصبح أى من الأعراض الجانبية جسيماً أو إذا تعرضت لأى أعراض جانبية أخرى غير المذكورة فى هذه النشرة, فضلاً أخبر طبيبك المعالج أو الصيدلى.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>يحفظ هذا الدواء بعيداً عن متناول ونظر الأطفال.</p><p>لا يستخدم لاجونا بعد انتهاء تاريخ الصلاحية المدون على الملصق والعبوة. تاريخ الانتهاء يشير إلى آخر يوم فى الشهر المذكور.</p><p>بالنسبة لكبسولات لاجونا فى الزجاجة:</p><p>يحفظ هذا الدواء فى درجة حرارة أقل من 30 درجة مئوية.</p><p>تحفظ الكبسولات فى الزجاجة الأصلية لحمايتها من الرطوبة.</p><p>يجب الحفاظ على إبقاء الزجاجة مغلقة بإحكام.</p><p>بالنسبة لكبسولات لاجونا فى الأكياس:</p><p>يحفظ هذا الدواء فى درجة حرارة أقل من 30 درجة مئوية.</p><p>&nbsp;</p><p>يجب عدم التخلص من الأدوية في مياه المجاري أو قمامة المنزل. اسأل الصيدلي عن كيفية التخلص من الأدوية التي لم تعد بحاجة إليها. لأن هذه الاعتبارات ستعمل على حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المادة الفعالة هى تيموزولومايد.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لاجونا 5 ملجم كبسولات صلبة: تحتوى كل كبسولة على 5 ملجم من مادة تيموزولومايد.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لاجونا 20 ملجم كبسولات صلبة: تحتوى كل كبسولة على 20 ملجم من مادة تيموزولومايد.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لاجونا 100 ملجم كبسولات صلبة: تحتوى كل كبسولة على 100 ملجم من مادة تيموزولومايد.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لاجونا 140 ملجم كبسولات صلبة: تحتوى كل كبسولة على 140 ملجم من مادة تيموزولومايد.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لاجونا 180 ملجم كبسولات صلبة: تحتوى كل كبسولة على 180 ملجم من مادة تيموزولومايد.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لاجونا 250 ملجم كبسولات صلبة: تحتوى كل كبسولة على 250 ملجم من مادة تيموزولومايد.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مكونات أخرى وهى:</p><p>محتوي الكبسولة</p><p>لاكتوز لامائي,</p><p>ثاني أكسيد سيليكون غروى,</p><p>جلايكولات نشا الصوديوم (نوع أ),</p><p>حمض طرطريك,</p><p>حمض دهني,</p><p>صدفة الكبسولة, حجم 0:</p><p>لاجونا 5 ملجم كبسولات صلبة: جيلاتين، ثاني أكسيد تيتانيوم (E 171). أكسيد حديد أصفر (E 172), أكسيد حديد أحمر (E 172).</p><p>لاجونا 20 ملجم كبسولات صلبة: جيلاتين, ثاني أكسيد تيتانيوم (E 171), وأكسيد حديد أحمر (E 172), أكسيد حديد أصفر (E 172).</p><p>لاجونا 100 ملجم كبسولات صلبة: جيلاتين, ثاني أكسيد تيتانيوم (E 171), إنديجوتين FD&amp;C, أزرق (E 132).</p><p>لاجونا 140 ملجم كبسولات صلبة: جيلاتين, ثاني أكسيد تيتانيوم (E 171), إنديجوتين FD&amp;C, أزرق (E 132).</p><p>لاجونا 180 ملجم كبسولات صلبة: جيلاتين, ثاني أكسيد تيتانيوم (E 171), أكسيد حديد أصفر (E 172), أكسيد حديد أحمر (E 172), أكسيد حديد أسود (E 172).</p><p>لاجونا 250 ملجم كبسولات صلبة: جيلاتين, ثاني أكسيد تيتانيوم (E 171).</p><p>حبر الطباعة</p><p>صمغ اللك, كحول مجفف, كحول الأيزوبروبيل, كحول بيوتايل, بروبيلين جليكول, مياه نقية, محلول أمونيا الصوديوم, هيدروكسيد بوتاسيوم, وأكسيد حديد أسود (E 172).</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p>لاجونا 5 ملجم كبسولات صلبة: كبسولات جيلاتين صلبة حجم 0 (لها غطاء أخضر اللون غير شفاف/جسم الكبسولة أبيض غير شفاف) مطبوع علي جسم الكبسولة رقم 5. لاجونا 20 ملجم كبسولات صلبة: كبسولات جيلاتين صلبة حجم 0 (لها غطاء برتقالى اللون غير شفاف/جسم الكبسولة أبيض غير شفاف) مطبوع علي جسم الكبسولة رقم 20. لاجونا 100 ملجم كبسولات صلبة: كبسولات جيلاتين صلبة حجم 0 (لها غطاء بنفسجى اللون غير شفاف/جسم الكبسولة أبيض غير شفاف) مطبوع علي جسم الكبسولة رقم 100. لاجونا 140 ملجم كبسولات صلبة: كبسولات جيلاتين صلبة حجم 0 (لها غطاء أزرق اللون غير شفاف/جسم الكبسولة أبيض غير شفاف) مطبوع علي جسم الكبسولة رقم 140. لاجونا 180 ملجم كبسولات صلبة: كبسولات جيلاتين صلبة حجم 0 (لها غطاء لونه بنى شوكولاتة غير شفاف/جسم الكبسولة أبيض غير شفاف) مطبوع علي جسم الكبسولة رقم 180. لاجونا 250 ملجم كبسولات صلبة: كبسولات جيلاتين صلبة حجم 0 (لها غطاء أبيض اللون غير شفاف/جسم الكبسولة أبيض غير شفاف) مطبوع علي جسم الكبسولة رقم 250. شكل زجاجة لاجونا: زجاجات بولى إيثيلين عالى الكثافة لونها أبيض غير شفاف مع غطاء من بولى بروبيلين يحكم غلقه بالضغط, مع لفائف البوليستر تحتوي كل زجاجة على 5 كبسولات. شكل أكياس لاجونا: كيس يتكون من ورق على بولي إيثيلين منخفض الكثافة (الطبقة الخارجية), وألومنيوم وبوليمر إيثيلين حمض الأكريليك (الطبقة الداخلية). يحتوي كل كيس على كبسولة واحدة صلبة تصرف في كرتون من الورق المقوى. الكرتون يحتوي على 5 كبسولات أو 20 كبسولة صلبة, محفوظة بشكل فردي في كيس. قد لا يتم تسويق جميع أحجام العبوات.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p><strong>صنع بواسطة: إيرجن فارما المحدودة</strong></p><p><strong>&nbsp;</strong></p><p><strong>لصالح:</strong> <strong>الدوائية</strong></p><p>مصنع الأدوية بالقصيم،</p><p>الشركة السعودية للصناعات الدوائية والمستلزمات الطبية،</p><p>المملكة العربية السعودية.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            نوفمبر 2017.            
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Lagona 5 mg, 20 mg, 100 mg, 140 mg, 180 mg, or 250 mg hard capsules
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each hard capsule contains 5 mg, 20 mg, 100 mg, 140, 180 mg or 250 mg temozolomide.
Excipient with known effect:
Each 5 mg hard capsule contains 399.3 mg of anhydrous lactose.
Each 20 mg hard capsule contains 384.3 mg of anhydrous lactose.
Each 100 mg hard capsule contains 61.7 mg of anhydrous lactose
Each 140 mg hard capsule contains 86.4 mg of anhydrous lactose.
Each 180 mg hard capsule contains 111.1 mg of anhydrous lactose.
Each 250 mg hard capsule contains 154.3 mg of anhydrous lactose.
For the full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hard capsule (capsule).
− Lagona 5 mg hard capsules: Hard gelatin capsules size 0 (green opaque cap/white opaque
body) with 5 printed on the body.
− Lagona 20 mg hard capsules: Hard gelatin capsules size 0 (orange opaque cap /white
opaque body) with 20 printed on the body.
− Lagona 100 mg hard capsules: Hard gelatin capsules size 0 (purple opaque cap /white
opaque body) with 100 printed on the body.
− Lagona 140 mg hard capsules: Hard gelatin capsules size 0 (blue opaque cap /white opaque
body) with 140 printed on the body.
− Lagona 180 mg hard capsules: Hard gelatin capsules size 0 (chocolate brown opaque cap
/white opaque body) with 180 printed on the body.
− Lagona 250 mg hard capsules: Hard gelatin capsules size 0 (white opaque cap /white
opaque body) with 250 printed on the body.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Lagona is indicated for the treatment of:</p><p>- Adult patients with newly-diagnosed glioblastoma multiforme concomitantly with radiotherapy (RT) and subsequently as monotherapy treatment.</p><p>- Children from the age of three years, adolescents and adult patients with malignant glioma, such as glioblastoma multiforme or anaplastic astrocytoma, showing recurrence or progression after standard therapy.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Lagona should only be prescribed by physicians experienced in the oncological treatment of brain tumours.</p><p>Anti-emetic therapy may be administered (see section 4.4).</p><p><u>Posology</u></p><p><em><u>Adult patients with newly-diagnosed glioblastoma multiforme</u></em></p><p>Lagona is administered in combination with focal radiotherapy (concomitant phase) followed by up to 6 cycles of temozolomide (LAGONA) monotherapy (monotherapy phase).</p><p><em>Concomitant phase</em></p><p>Lagona is administered orally at a dose of 75 mg/m<sup>2</sup>&nbsp;daily for 42 days concomitant with focal radiotherapy (60 Gy administered in 30 fractions). No dose reductions are recommended, but delay or discontinuation of Lagona administration should be decided weekly according to haematological and non-haematological toxicity criteria. Lagona administration can be continued throughout the 42 day concomitant period (up to 49 days) if all of the following conditions are met:</p><p>- Absolute neutrophil count (ANC) &ge; 1.5 x 10<sup>9</sup>/l</p><p>- Thrombocyte count &ge; 100 x 10<sup>9</sup>/l</p><p>- Common toxicity criteria (CTC) non-haematological toxicity &le; Grade 1 (except for alopecia, nausea and vomiting).</p><p>During treatment a complete blood count should be obtained weekly. Lagona administration should be temporarily interrupted or permanently discontinued during the concomitant phase according to the haematological and non-haematological toxicity criteria as noted in Table 1.</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="3"><p><em>Table 1. Lagona</em> <em>dosing interruption or discontinuation during concomitant radiotherapy and LAGONA</em></p></td></tr><tr><td><p>Toxicity</p></td><td><p>Lagona interruption<sup>a</sup></p></td><td><p>Lagona discontinuation</p></td></tr><tr><td><p>Absolute neutrophil count</p></td><td><p>&ge; 0.5 and &lt; 1.5 x 10<sup>9</sup>/l</p></td><td><p>&lt; 0.5 x 10<sup>9</sup>/l</p></td></tr><tr><td><p>Thrombocyte count</p></td><td><p>&ge; 10 and &lt; 100 x 10<sup>9</sup>/l</p></td><td><p>&lt; 10 x 10<sup>9</sup>/l</p></td></tr><tr><td><p>CTC non-haematological toxicity (except for alopecia, nausea, vomiting)</p></td><td><p>CTC Grade 2</p></td><td><p>CTC Grade 3 or 4</p></td></tr></tbody></table><p>a: Treatment with concomitant Lagona can be continued when all of the following conditions are met: absolute neutrophil count &ge; 1.5 x 10<sup>9</sup>/l; thrombocyte count &ge; 100 x 10<sup>9</sup>/l; CTC non-haematological toxicity &le; Grade 1 (except for alopecia, nausea, vomiting).</p><p><em>Monotherapy phase</em></p><p>Four weeks after completing the Lagona + RT concomitant phase, Lagona is administered for up to 6 cycles of monotherapy treatment. Dose in Cycle 1 (monotherapy) is 150 mg/m<sup>2</sup>&nbsp;once daily for 5 days followed by 23 days without treatment. At the start of Cycle 2, the dose is escalated to 200 mg/m<sup>2&nbsp;</sup>if the CTC non-haematological toxicity for Cycle 1 is Grade &le; 2 (except for alopecia, nausea and vomiting), absolute neutrophil count (ANC) is &ge; 1.5 x 10<sup>9</sup>/l, and the thrombocyte count is &ge; 100 x 10<sup>9</sup>/l. If the dose was not escalated at Cycle 2, escalation should not be done in subsequent cycles. Once escalated, the dose remains at 200 mg/m<sup>2</sup>&nbsp;per day for the first 5 days of each subsequent cycle except if toxicity occurs. Dose reductions and discontinuations during the monotherapy phase should be applied according to Tables 2 and 3.</p><p>During treatment a complete blood count should be obtained on Day 22 (21 days after the first dose of Lagona). The dose should be reduced or administration discontinued according to Table 3.</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="3"><p><em>Table 2. Lagona dose levels for monotherapy treatment</em></p></td></tr><tr><td><p>Dose level</p></td><td><p>Lagona dose (mg/m<sup>2</sup>/day)</p></td><td><p>Remarks</p></td></tr><tr><td><p>&ndash;1</p></td><td><p>100</p></td><td><p>Reduction for prior toxicity</p></td></tr><tr><td><p>0</p></td><td><p>150</p></td><td><p>Dose during Cycle 1</p></td></tr><tr><td><p>1</p></td><td><p>200</p></td><td><p>Dose during Cycles 2-6 in absence of toxicity</p></td></tr></tbody></table><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="3"><p><em>Table 3. Lagona dose reduction or discontinuation during monotherapy treatment</em></p></td></tr><tr><td><p>Toxicity</p></td><td><p>Reduce Lagona by 1 dose level<sup>a</sup></p></td><td><p>Discontinue Lagona</p></td></tr><tr><td><p>Absolute neutrophil count</p></td><td><p>&lt; 1.0 x 10<sup>9</sup>/l</p></td><td><p>See footnote b</p></td></tr><tr><td><p>Thrombocyte count</p></td><td><p>&lt; 50 x 10<sup>9</sup>/l</p></td><td><p>See footnote b</p></td></tr><tr><td><p>CTC non-haematological Toxicity (except for alopecia, nausea, vomiting)</p></td><td><p>CTC Grade 3</p></td><td><p>CTC Grade 4<sup>b</sup></p></td></tr></tbody></table><p>a: Lagona dose levels are listed in Table 2.</p><p>b: Lagona is to be discontinued if:</p><p>&bull; Dose level -1 (100 mg/m<sup>2</sup>) still results in unacceptable toxicity</p><p>&bull; The same Grade 3 non-haematological toxicity (except for alopecia, nausea, vomiting) recurs after dose reduction.</p><p><em><u>Adult and paediatric patients 3 years of age or older with recurrent or progressive malignant glioma</u></em>:</p><p>A treatment cycle comprises 28 days. In patients previously untreated with chemotherapy, Lagona is administered orally at a dose of 200 mg/m<sup>2</sup>&nbsp;once daily for the first 5 days followed by a 23 day treatment interruption (total of 28 days). In patients previously treated with chemotherapy, the initial dose is 150 mg/m<sup>2</sup>&nbsp;once daily, to be increased in the second cycle to 200 mg/m<sup>2</sup>&nbsp;once daily, for 5 days if there is no haematological toxicity (see section 4.4)</p><p><em><u>Special populations</u></em></p><p><em>Paediatric population</em></p><p>In patients 3 years of age or older, Lagona is only to be used in recurrent or progressive malignant glioma. Experience in these children is very limited (see sections 4.4 and 5.1). The safety and efficacy of Lagona in children under the age of 3 years have not been established. No data are available.</p><p><em>Patients with hepatic or renal impairment</em></p><p>The pharmacokinetics of Lagona were comparable in patients with normal hepatic function and in those with mild or moderate hepatic impairment. No data are available on the administration of Lagona in patients with severe hepatic impairment (Child&#39;s Class C) or with renal impairment. Based on the pharmacokinetic properties of Lagona, it is unlikely that dose reductions are required in patients with severe hepatic impairment or any degree of renal impairment. However, caution should be exercised when Lagona is administered in these patients.</p><p><em>Elderly patients</em></p><p>Based on a population pharmacokinetic analysis in patients 19-78 years of age, clearance of Lagona is not affected by age. However, elderly patients (&gt; 70 years of age) appear to be at increased risk of neutropenia and thrombocytopenia (see section 4.4).</p><p><u>Method of administration</u></p><p>Lagona hard capsules should be administered in the fasting state.</p><p>The capsules must be swallowed whole with a glass of water and must not be opened or chewed.</p><p>If vomiting occurs after the dose is administered, a second dose should not be administered that day.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
Hypersensitivity to dacarbazine (DTIC).
Severe myelosuppression (see section 4.4).

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em><u>Opportunistic infections and reactivation of infections</u></em></p><p>Opportunistic infections (such as Pneumocystis jirovecii pneumonia) and reactivation of infections (such as HBV, CMV) have been observed during the treatment with Lagona (see section 4.8).</p><p>&nbsp;</p><p><em><u>Meningoencephalitis herpetic</u></em></p><p>In post marketing cases, meningoencephalitis herpetic (including fatal cases) has been observed in patients receiving Lagona in combination with radiotherapy, including cases of concomitant steroids administration.</p><p>&nbsp;</p><p><em><u>Pneumocystis jirovecii&nbsp;</u></em><u>pneumonia</u></p><p>Patients who received concomitant Lagona and RT in a pilot trial for the prolonged 42-day schedule were shown to be at particular risk for developing&nbsp;<em>Pneumocystis jirovecii</em>&nbsp;pneumonia (PCP). Thus, prophylaxis against PCP is required for all patients receiving concomitant Lagona and RT for the 42-day regimen (with a maximum of 49 days) regardless of lymphocyte count. If lymphopenia occurs, they are to continue the prophylaxis until recovery of lymphopenia to grade &le; 1.</p><p>There may be a higher occurrence of PCP when Lagona is administered during a longer dosing regimen. However, all patients receiving Lagona, particularly patients receiving steroids, should be observed closely for the development of PCP, regardless of the regimen. Cases of fatal respiratory failure have been reported in patients using Lagona, in particular in combination with dexamethasone or other steroids.</p><p><u>HBV</u></p><p>Hepatitis due to hepatitis B virus (HBV) reactivation, in some cases resulting in death, has been reported. Experts in liver disease should be consulted before treatment is initiated in patients with positive hepatitis B serology (including those with active disease). During treatment patients should be monitored and managed appropriately.</p><p><u>Hepatotoxicity</u></p><p>Hepatic injury, including fatal hepatic failure, has been reported in patients treated with Lagona (see section 4.8). Baseline liver function tests should be performed prior to treatment initiation. If abnormal, physicians should assess the benefit/risk prior to initiating temozolomide including the potential for fatal hepatic failure. For patients on a 42 day treatment cycle liver function tests should be repeated midway during this cycle. For all patients, liver function tests should be checked after each treatment cycle. For patients with significant liver function abnormalities, physicians should assess the benefit/risk of continuing treatment. Liver toxicity may occur several weeks or more after the last treatment with temozolomide.</p><p><u>Malignancies</u></p><p>Cases of myelodysplastic syndrome and secondary malignancies, including myeloid leukaemia, have also been reported very rarely (see section 4.8).</p><p><u>Anti-emetic therapy</u></p><p>Nausea and vomiting are very commonly associated with Lagona.</p><p>Anti-emetic therapy may be administered prior to or following administration of Lagona.</p><p><em><u>Adult patients with newly-diagnosed glioblastoma multiforme</u></em></p><p>Anti-emetic prophylaxis is recommended prior to the initial dose of concomitant phase and it is strongly recommended during the monotherapy phase.</p><p><em><u>Patients with recurrent or progressive malignant glioma</u></em></p><p>Patients who have experienced severe (Grade 3 or 4) vomiting in previous treatment cycles may require anti-emetic therapy.</p><p><u>Laboratory parameters</u></p><p>Patients treated with Lagona may experience myelosuppression, including prolonged pancytopenia, which may result in aplastic anemia, which in some cases has resulted in a fatal outcome. In some cases, exposure to concomitant medicinal products associated with aplastic anemia, including carbamazepine, phenytoin, and sulfamethoxazole/trimethoprim, complicates assessment. Prior to dosing, the following laboratory parameters must be met: ANC &ge; 1.5 x 10<sup>9</sup>/l and platelet count &ge; 100 x 10<sup>9</sup>/l. A complete blood count should be obtained on Day 22 (21 days after the first dose) or within 48 hours of that day, and weekly until ANC &gt; 1.5 x 10<sup>9</sup>/l and platelet count &gt; 100 x 10<sup>9</sup>/l. If ANC falls to &lt; 1.0 x 10<sup>9</sup>/l or the platelet count is &lt; 50 x 10<sup>9</sup>/l during any cycle, the next cycle should be reduced one dose level (see section 4.2). Dose levels include 100 mg/m<sup>2</sup>, 150 mg/m<sup>2</sup>, and 200 mg/m<sup>2</sup>. The lowest recommended dose is 100 mg/m<sup>2</sup>.</p><p><u>Paediatric population</u></p><p>There is no clinical experience with use of Lagona in children under the age of 3 years. Experience in older children and adolescents is very limited (see sections 4.2 and 5.1).</p><p><u>Elderly patients (&gt; 70 years of age)</u></p><p>Elderly patients appear to be at increased risk of neutropenia and thrombocytopenia, compared with younger patients. Therefore, special care should be taken when Lagona is administered in elderly patients.</p><p><u>Male patients</u></p><p>Men being treated with Lagona should be advised not to father a child up to 6 months after receiving the last dose and to seek advice on cryoconservation of sperm prior to treatment (see section 4.6).</p><p><u>Lactose</u></p><p>This medicinal product contains lactose. Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In a separate phase I study, administration of Lagona with ranitidine did not result in alterations in the extent of absorption of temozolomide or the exposure to its active metabolite monomethyl triazenoimidazole carboxamide (MTIC).</p><p>Administration of Lagona with food resulted in a 33 % decrease in C<sub>max</sub>&nbsp;and a 9 % decrease in area under the curve (AUC).</p><p>As it cannot be excluded that the change in C<sub>max</sub>&nbsp;is clinically significant, Lagona should be administered without food.</p><p>Based on an analysis of population pharmacokinetics in phase II trials, co-administration of dexamethasone, prochlorperazine, phenytoin, carbamazepine, ondansetron, H<sub>2</sub>&nbsp;receptor antagonists, or phenobarbital did not alter the clearance of Lagona. Co-administration with valproic acid was associated with a small but statistically significant decrease in clearance of Lagona.</p><p>No studies have been conducted to determine the effect of Lagona on the metabolism or elimination of other medicinal products. However, since Lagona does not undergo hepatic metabolism and exhibits low protein binding, it is unlikely that it would affect the pharmacokinetics of other medicinal products (see section 5.2).</p><p>Use of Lagona in combination with other myelosuppressive agents may increase the likelihood of myelosuppression.</p><p><u>Paediatric population</u></p><p>Interaction studies have only been performed in adults.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pregnancy</u></p><p>Pregnancy category: D.</p><p>There are no data in pregnant women. In preclinical studies in rats and rabbits receiving 150 mg/m<sup>2&nbsp;</sup>Lagona, teratogenicity and/or foetal toxicity were demonstrated (see section 5.3). Lagona should not be administered to pregnant women. If use during pregnancy must be considered, the patient should be apprised of the potential risk to the foetus.</p><p><u>Breast-feeding</u></p><p>It is not known whether Lagona is excreted in human milk; thus, breast-feeding should be discontinued while receiving treatment with Lagona.</p><p><u>Women of childbearing potential</u></p><p>Women of childbearing potential should be advised to use effective contraception to avoid pregnancy while they are receiving Lagona.</p><p><u>Male fertility</u></p><p>Lagona can have genotoxic effects. Therefore, men being treated with it should be advised not to father a child up to 6 months after receiving the last dose and to seek advice on cryoconservation of sperm prior to treatment, because of the possibility of irreversible infertility due to therapy with Lagona.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Lagona has minor influence on the ability to drive and use machines due to fatigue and somnolence (see section 4.8).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Clinical trial experience</u></p><p>In patients treated with Lagona, whether used in combination with RT or as monotherapy following RT for newly-diagnosed glioblastoma multiforme, or as monotherapy in patients with recurrent or progressive glioma, the reported very common adverse reactions were similar: nausea, vomiting, constipation, anorexia, headache and fatigue. Convulsions were reported very commonly in the newly-diagnosed glioblastoma multiforme patients receiving monotherapy, and rash was reported very commonly in newly-diagnosed glioblastoma multiforme patients receiving Lagona concurrent with RT and also as monotherapy, and commonly in recurrent glioma. Most haematologic adverse reactions were reported commonly or very commonly in both indications (Tables 4 and 5); the frequency of grade 3-4 laboratory findings is presented after each table.</p><p>In the tables undesirable effects are classified according to System Organ Class and frequency. Frequency groupings are defined according to the following convention: Very common (&ge; 1/10); Common (&ge; 1/100 to &lt; 1/10); Uncommon (&ge; 1/1,000 to &lt; 1/100); Rare (&ge;1/10,000 to &lt;1/1,000); Very rare (&lt;1/10,000). Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness.</p><p><em><u>Newly-diagnosed glioblastoma multiforme</u></em></p><p>Table 4 provides treatment-emergent adverse events in patients with newly-diagnosed glioblastoma multiforme during the concomitant and monotherapy phases of treatment.</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="3"><p><em>Table 4. Treatment-emergent events during concomitant and monotherapy treatment phases in patients with newly-diagnosed glioblastoma multiforme</em></p></td></tr><tr><td><p>System organ class</p></td><td><p>Lagona + concomitant RT</p><p>n=288*</p></td><td><p>Lagona monotherapy</p><p>n=224</p></td></tr><tr><td colspan="3"><p>Infections and infestations</p></td></tr><tr><td><p>Common:</p></td><td><p>Infection<em>, Herpes simplex</em>, wound infection, pharyngitis, candidiasis oral</p></td><td><p>Infection, candidiasis oral</p></td></tr><tr><td><p>Uncommon:</p></td><td><p>&nbsp;</p></td><td><p><em>Herpes simplex</em>, herpes zoster, influenza&ndash;like symptoms</p></td></tr><tr><td colspan="3"><p>Blood and lymphatic system disorders</p></td></tr><tr><td><p>Common:</p></td><td><p>Neutropenia, thrombocytopenia, lymphopenia, leukopenia</p></td><td><p>Febrile neutropenia, thrombocytopenia, anaemia, leukopenia</p></td></tr><tr><td><p>Uncommon:</p></td><td><p>Febrile neutropenia, anaemia</p></td><td><p>Lymphopenia, petechiae</p></td></tr><tr><td colspan="3"><p>Endocrine disorders</p></td></tr><tr><td><p>Uncommon:</p></td><td><p>Cushingoid</p></td><td><p>Cushingoid</p></td></tr><tr><td colspan="3"><p>Metabolism and nutrition disorders</p></td></tr><tr><td><p>Very common:</p></td><td><p>Anorexia</p></td><td><p>Anorexia</p></td></tr><tr><td><p>Common:</p></td><td><p>Hyperglycaemia, weight decreased</p></td><td><p>Weight decreased</p></td></tr><tr><td><p>Uncommon:</p></td><td><p>Hypokalemia, alkaline phosphatase increased, weight increased</p></td><td><p>Hyperglycaemia, weight increased</p></td></tr><tr><td colspan="3"><p>Psychiatric disorders</p></td></tr><tr><td><p>Common:</p></td><td><p>Anxiety, emotional lability, insomnia</p></td><td><p>Anxiety, depression, emotional lability, insomnia</p></td></tr><tr><td><p>Uncommon:</p></td><td><p>Agitation, apathy, behaviour disorder, depression, hallucination</p></td><td><p>Hallucination, amnesia</p></td></tr><tr><td colspan="3"><p>Nervous system disorders</p></td></tr><tr><td><p>Very common:</p></td><td><p>Headache</p></td><td><p>Convulsions, headache</p></td></tr><tr><td><p>Common:</p></td><td><p>Convulsions, consciousness decreased, somnolence, aphasia, balance impaired, dizziness, confusion, memory impairment, concentration impaired, neuropathy, paresthesia, speech disorder, tremor</p></td><td><p>Hemiparesis, aphasia, balance impaired, somnolence, confusion, dizziness, memory impairment, concentration impaired, dysphasia, neurological disorder (NOS), neuropathy, peripheral neuropathy, paresthesia, speech disorder, tremor</p></td></tr><tr><td><p>Uncommon:</p></td><td><p>Status epilepticus, extrapyramidal disorder, hemiparesis, ataxia, cognition impaired, dysphasia, gait abnormal, hyperesthesia, hypoesthesia, neurological disorder (NOS), peripheral neuropathy</p></td><td><p>Hemiplegia, ataxia, coordination abnormal, gait abnormal, hyperesthesia, sensory disturbance</p></td></tr><tr><td colspan="3"><p>Eye disorders</p></td></tr><tr><td><p>Common:</p></td><td><p>Vision blurred</p></td><td><p>Visual field defect, vision blurred, diplopia</p></td></tr><tr><td><p>Uncommon:</p></td><td><p>Hemianopia, visual acuity reduced, vision disorder, visual field defect, eye pain</p></td><td><p>Visual acuity reduced, eye pain, eyes dry</p></td></tr><tr><td colspan="3"><p>Ear and labyrinth disorders</p></td></tr><tr><td><p>Common:</p></td><td><p>Hearing impairment</p></td><td><p>Hearing impairment, tinnitus</p></td></tr><tr><td><p>Uncommon:</p></td><td><p>Otitis media, tinnitus, hyperacusis, earache</p></td><td><p>Deafness, vertigo, earache</p></td></tr><tr><td colspan="3"><p>Cardiac disorders</p></td></tr><tr><td><p>Uncommon:</p></td><td><p>Palpitation</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="3"><p>Vascular disorders</p></td></tr><tr><td><p>Common:</p></td><td><p>Haemorrhage, oedema, oedema leg</p></td><td><p>Haemorrhage, deep venous thrombosis, oedema leg</p></td></tr><tr><td><p>Uncommon:</p></td><td><p>Cerebral haemorrhage, hypertension</p></td><td><p>Embolism pulmonary, oedema, oedema peripheral</p></td></tr><tr><td colspan="3"><p>Respiratory, thoracic and mediastinal disorders</p></td></tr><tr><td><p>Common:</p></td><td><p>Dyspnoea, coughing</p></td><td><p>Dyspnoea, coughing</p></td></tr><tr><td><p>Uncommon:</p></td><td><p>Pneumonia, upper respiratory infection, nasal congestion</p></td><td><p>Pneumonia, sinusitis, upper respiratory infection, bronchitis</p></td></tr><tr><td colspan="3"><p>Gastrointestinal disorders</p></td></tr><tr><td><p>Very common:</p></td><td><p>Constipation, nausea, vomiting</p></td><td><p>Constipation, nausea, vomiting</p></td></tr><tr><td><p>Common:</p></td><td><p>Stomatitis, diarrhoea, abdominal pain, dyspepsia, dysphagia</p></td><td><p>Stomatitis, diarrhoea, dyspepsia, dysphagia, mouth dry</p></td></tr><tr><td><p>Uncommon:</p></td><td><p>&nbsp;</p></td><td><p>Abdominal distension, fecal incontinence, gastrointestinal disorder (NOS), gastroenteritis, haemorrhoids</p></td></tr><tr><td colspan="3"><p>Skin and subcutaneous tissue disorders</p></td></tr><tr><td><p>Very common:</p></td><td><p>Rash, alopecia</p></td><td><p>Rash, alopecia</p></td></tr><tr><td><p>Common:</p></td><td><p>Dermatitis, dry skin, erythema, pruritus</p></td><td><p>Dry skin, pruritus</p></td></tr><tr><td><p>Uncommon:</p></td><td><p>Skin exfoliation, photosensitivity reaction, pigmentation abnormal</p></td><td><p>Erythema, pigmentation abnormal, sweating increased</p></td></tr><tr><td colspan="3"><p>Musculoskeletal and connective tissue disorders</p></td></tr><tr><td><p>Common:</p></td><td><p>Muscle weakness, arthralgia</p></td><td><p>Muscle weakness, arthralgia, musculoskeletal pain, myalgia</p></td></tr><tr><td><p>Uncommon:</p></td><td><p>Myopathy, back pain, musculoskeletal pain, myalgia</p></td><td><p>Myopathy, back pain</p></td></tr><tr><td colspan="3"><p>Renal and urinary disorders</p></td></tr><tr><td><p>Common:</p></td><td><p>Micturition frequency, urinary incontinence</p></td><td><p>Urinary incontinence</p></td></tr><tr><td><p>Uncommon:</p></td><td><p>&nbsp;</p></td><td><p>Dysuria</p></td></tr><tr><td colspan="3"><p>Reproductive system and breast disorders</p></td></tr><tr><td><p>Uncommon:</p></td><td><p>Impotence</p></td><td><p>Vaginal haemorrhage,menorrhagia, amenorrhea, vaginitis, breast pain</p></td></tr><tr><td colspan="3"><p>General disorders and administration site conditions</p></td></tr><tr><td><p>Very common:</p></td><td><p>Fatigue</p></td><td><p>Fatigue</p></td></tr><tr><td><p>Common:</p></td><td><p>Allergic reaction, fever, radiation injury, face oedema, pain, taste perversion</p></td><td><p>Allergic reaction, fever, radiation injury, pain, taste perversion</p></td></tr><tr><td><p>Uncommon:</p></td><td><p>Asthenia, flushing, hot flushes, condition aggravated, rigors, tongue discolouration, parosmia, thirst</p></td><td><p>Asthenia, face oedema, pain, condition aggravated, rigors, tooth disorder</p></td></tr><tr><td colspan="3"><p>Investigations</p></td></tr><tr><td><p>Common:</p></td><td><p>ALT increased</p></td><td><p>ALT increased</p></td></tr><tr><td><p>Uncommon:</p></td><td><p>Hepatic enzymes increased, Gamma GT increased, AST increased</p></td><td><p>&nbsp;</p></td></tr></tbody></table><p>*A patient who was randomised to the RT arm only received Lagona + RT.</p><p><em>Laboratory results</em></p><p>Myelosuppression (neutropenia and thrombocytopenia), which is known dose-limiting toxicity for most cytotoxic agents, including Lagona, was observed. When laboratory abnormalities and adverse events were combined across concomitant and monotherapy treatment phases, Grade 3 or Grade 4 neutrophil abnormalities including neutropenic events were observed in 8 % of the patients. Grade 3 or Grade 4 thrombocyte abnormalities, including thrombocytopenic events were observed in 14 % of the patients who received Lagona.</p><p><em><u>Recurrent or progressive malignant glioma</u></em></p><p>In clinical trials, the most frequently occurring treatment-related undesirable effects were gastrointestinal disorders, specifically nausea (43 %) and vomiting (36 %). These reactions were usually Grade 1 or 2 (0 &ndash; 5 episodes of vomiting in 24 hours) and were either self-limiting or readily controlled with standard anti-emetic therapy. The incidence of severe nausea and vomiting was 4 %.</p><p>Table 5 includes adverse reactions reported during clinical trials for recurrent or progressive malignant glioma and following the marketing of Lagona.</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="2"><p><em>Table 5. Adverse reactions in patients with recurrent or progressive malignant glioma</em></p></td></tr><tr><td colspan="2"><p>Infections and infestations</p></td></tr><tr><td><p>Rare:</p></td><td><p>Opportunistic infections, including PCP</p></td></tr><tr><td colspan="2"><p>Blood and lymphatic system disorders</p></td></tr><tr><td><p>Very common:</p></td><td><p>Neutropenia or lymphopenia (grade 3-4), thrombocytopenia (grade 3-4)</p></td></tr><tr><td><p>Uncommon:</p></td><td><p>Pancytopenia, anaemia (grade 3-4), leukopenia</p></td></tr><tr><td colspan="2"><p>Metabolism and nutrition disorders</p></td></tr><tr><td><p>Very common:</p></td><td><p>Anorexia</p></td></tr><tr><td><p>Common:</p></td><td><p>Weight decrease</p></td></tr><tr><td colspan="2"><p>Nervous system disorders</p></td></tr><tr><td><p>Very common:</p></td><td><p>Headache</p></td></tr><tr><td><p>Common:</p></td><td><p>Somnolence, dizziness, paresthesia</p></td></tr><tr><td colspan="2"><p>Respiratory, thoracic and mediastinal disorders</p></td></tr><tr><td><p>Common:</p></td><td><p>Dyspnoea</p></td></tr><tr><td colspan="2"><p>Gastrointestinal disorders</p></td></tr><tr><td><p>Very common:</p></td><td><p>Vomiting, nausea, constipation</p></td></tr><tr><td><p>Common:</p></td><td><p>Diarrhoea, abdominal pain, dyspepsia</p></td></tr><tr><td colspan="2"><p>Skin and subcutaneous tissue disorders</p></td></tr><tr><td><p>Common:</p></td><td><p>Rash, pruritus, alopecia</p></td></tr><tr><td><p>Very rare:</p></td><td><p>Erythema multiforme, erythroderma, urticaria, exanthema</p></td></tr><tr><td colspan="2"><p>General disorders and administration site conditions</p></td></tr><tr><td><p>Very common:</p></td><td><p>Fatigue</p></td></tr><tr><td><p>Common:</p></td><td><p>Fever, asthenia, rigors, malaise, pain, taste perversion</p></td></tr><tr><td><p>Very rare:</p></td><td><p>Allergic reactions, including anaphylaxis, angioedema</p></td></tr></tbody></table><p><em>Laboratory results</em></p><p>Grade 3 or 4 thrombocytopenia and neutropenia occurred in 19 % and 17 % respectively, of patients treated for malignant glioma. This led to hospitalisation and/or discontinuation of Lagona in 8 % and 4 %, respectively. Myelosuppression was predictable (usually within the first few cycles, with the nadir between Day 21 and Day 28), and recovery was rapid, usually within 1-2 weeks. No evidence of cumulative myelosuppression was observed. The presence of thrombocytopenia may increase the risk of bleeding, and the presence of neutropenia or leukopenia may increase the risk of infection.</p><p><em>Gender</em></p><p>In a population pharmacokinetics analysis of clinical trial experience there were 101 female and 169 male subjects for whom nadir neutrophil counts were available and 110 female and 174 male subjects for whom nadir platelet counts were available. There were higher rates of Grade 4 neutropenia (ANC &lt; 0.5 x 10<sup>9</sup>/l), 12 %&nbsp;<em>vs</em>&nbsp;5 %, and thrombocytopenia (&lt; 20 x 10<sup>9</sup>/l), 9 %&nbsp;<em>vs</em>&nbsp;3 %, in women&nbsp;<em>vs</em>&nbsp;men in the first cycle of therapy. In a 400 subject recurrent glioma data set, Grade 4 neutropenia occurred in 8 % of female&nbsp;<em>vs</em>&nbsp;4 % of male subjects and Grade 4 thrombocytopenia in 8 % of female&nbsp;<em>vs</em>&nbsp;3 % of male subjects in the first cycle of therapy. In a study of 288 subjects with newly-diagnosed glioblastoma multiforme, Grade 4 neutropenia occurred in 3 % of female&nbsp;<em>vs</em>&nbsp;0 % of male subjects and Grade 4 thrombocytopenia in 1 % of female&nbsp;<em>vs</em>&nbsp;0 % of male subjects in the first cycle of therapy.</p><p><u>Paediatric population</u></p><p>Oral Lagona has been studied in paediatric patients (age 3-18 years) with recurrent brainstem glioma or recurrent high grade astrocytoma, in a regimen administered daily for 5 days every 28 days. Although the data is limited, tolerance in children is expected to be the same as in adults. The safety of Lagona in children under the age of 3 years has not been established.</p><p><u>Post-Marketing Experience</u></p><p>The following additional serious adverse reactions have been identified during post-marketing exposure:</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="2"><p><em>Table 6. Summary of events reported with temozolomide in the post-marketing setting</em></p></td></tr><tr><td colspan="2"><p><strong>Infections and infestations</strong><sup>*</sup></p></td></tr><tr><td><p>Uncommon:</p></td><td><p>cytomegalovirus infection, infection reactivation such as cytomegalovirus, hepatitis B virus<sup>&dagger;</sup> , meningoencephalitis herpetic<sup>&dagger;</sup></p></td></tr><tr><td colspan="2"><p><strong>Blood and lymphatic system disorders</strong></p></td></tr><tr><td><p>Very rare:</p></td><td><p>prolonged pancytopenia, aplastic anaemia<sup>&dagger;</sup></p></td></tr><tr><td colspan="2"><p><strong>Neoplasm benign, malignant and unspecified</strong></p></td></tr><tr><td><p>Very rare:</p></td><td><p>myelodysplastic syndrome (MDS), secondary malignancies, including myeloid leukaemia</p></td></tr><tr><td colspan="2"><p><strong>Endocrine disorders</strong><sup>*</sup></p></td></tr><tr><td><p>Uncommon:</p></td><td><p>diabetes insipidus</p></td></tr><tr><td colspan="2"><p><strong>Respiratory, thoracic and mediastinal disorders</strong></p></td></tr><tr><td><p>Very rare:</p></td><td><p>interstitial pneumonitis/pneumonitis, pulmonary fibrosis, respiratory failure<sup>&dagger;</sup></p></td></tr><tr><td colspan="2"><p><strong>Hepatobiliary disorders</strong><sup>*</sup></p></td></tr><tr><td><p>Common:</p></td><td><p>liver enzymes elevations</p></td></tr><tr><td><p>Uncommon:</p></td><td><p>hyperbilirubinemia, cholestasis, hepatitis, hepatic injury, hepatic failure<sup>&dagger;</sup></p></td></tr><tr><td colspan="2"><p><strong>Skin and subcutaneous tissue disorders</strong></p></td></tr><tr><td><p>Very rare:</p></td><td><p>toxic epidermal necrolysis, Stevens-Johnson syndrome</p></td></tr></tbody></table><p>&dagger; Including cases with fatal outcome</p><p><sup>*&nbsp;</sup>Frequencies estimated based on relevant clinical trials.</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p><strong>To report any side effect(s):</strong></p><p> The National Pharmacovigilance and Drug Safety Centre (NPC)</p><p>o Fax: +966-11-205-7662</p><p>o Call NPC at +966-11-2038222, Exts: 2317-2356-2353-2354-2334-2340.</p><p>o Toll free phone: 8002490000</p><p>o E-mail: npc.drug@sfda.gov.sa</p><p>o Website: www.sfda.gov.sa/npc</p><p>&nbsp;</p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Doses of 500, 750, 1,000, and 1,250 mg/m<sup>2&nbsp;</sup>(total dose per cycle over 5 days) have been evaluated clinically in patients. Dose-limiting toxicity was haematological and was reported with any dose but is expected to be more severe at higher doses. An overdose of 10,000 mg (total dose in a single cycle, over 5 days) was taken by one patient and the adverse reactions reported were pancytopenia, pyrexia, multi-organ failure and death. There are reports of patients who have taken the recommended dose for more than 5 days of treatment (up to 64 days) with adverse events reported including bone marrow suppression, with or without infection, in some cases severe and prolonged and resulting in death. In the event of an overdose, haematological evaluation is needed. Supportive measures should be provided as necessary.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Antineoplastic agents - Other alkylating agents, ATC code: L01A X03</p><p><u>Mechanism of action</u></p><p>Temozolomide is a triazene, which undergoes rapid chemical conversion at physiologic pH to the active monomethyl triazenoimidazole carboxamide (MTIC). The cytotoxicity of MTIC is thought to be due primarily to alkylation at the O<sup>6</sup>position of guanine with additional alkylation also occurring at the N<sup>7</sup>&nbsp;position. Cytotoxic lesions that develop subsequently are thought to involve aberrant repair of the methyl adduct.</p><p><u>Clinical efficacy and safety</u></p><p><em><u>Newly-diagnosed glioblastoma multiforme</u></em></p><p>A total of 573 patients were randomised to receive either Lagona + RT (n=287) or RT alone (n=286). Patients in the Lagona + RT arm received concomitant Lagona (75 mg/m<sup>2</sup>) once daily, starting the first day of RT until the last day of RT, for 42 days (with a maximum of 49 days). This was followed by monotherapy Lagona (150 - 200 mg/m<sup>2</sup>) on Days 1 - 5 of every 28-day cycle for up to 6 cycles, starting 4 weeks after the end of RT. Patients in the control arm received RT only.&nbsp;<em>Pneumocystis jirovecii</em>pneumonia (PCP) prophylaxis was required during RT and combined Lagona therapy.</p><p>Lagona was administered as salvage therapy in the follow-up phase in 161 patients of the 282 (57 %) in the RT alone arm, and 62 patients of the 277 (22 %) in the Lagona + RT arm.</p><p>The hazard ratio (HR) for overall survival was 1.59 (95 % CI for HR=1.33 -1.91) with a log-rank p &lt; 0.0001 in favour of the Lagona arm. The estimated probability of surviving 2 years or more (26 %&nbsp;<em>vs</em>&nbsp;10 %) is higher for the RT + Lagona arm. The addition of concomitant Lagona to RT, followed by Lagona monotherapy in the treatment of patients with newly-diagnosed glioblastoma multiforme demonstrated a statistically significant improvement in overall survival (OS) compared with RT alone (Figure 1).</p><p><img alt="" width="708" height="382" src="data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAsQAAAF+CAYAAACF7AwNAAAAAXNSR0IArs4c6QAAAARnQU1BAACxjwv8YQUAAAAJcEhZcwAADsMAAA7DAcdvqGQAAD+dSURBVHhe7d3PayRZeu5x/Qn2wjAJZjbywuDaNRjaXpQWg2DoTW/amF5ooBiYRbcx44WgMEM3+EIxCGrjaQxtBOOBixuaBOO7mWkQhaEXLhDMNcNQaGOGnkJwaZpGCHdTFOLcfDLjVb06dSIyUorIOHHi+4EXZcY5GXkiMn48FRVK7YQQ9hb1IUVRFEVRFEVNsRSI9QAAAACYJAIxAAAAJo1ADAAAgEkjEAMAAGDSCMQAAACYNAIxAAAAJo1ADKBzT548CR988EH1DACAvBGIAXSOQAwAGBMCMQAAACaNQAwAAIBJIxADAABg0gjEAAAAmDQCMQAAACaNQAyM3M6OduMVPb5L1dE3RqT6b+ubJOz92oj7bfLaLtn7DvX+Jn5/PW7zudnrrPr+rPUed2VjBYBN6chBIAZGzAcAhRar+/fvXweZVFl48NPqWH/fV6X30M++2VjbiPvZWLfFxqry68mmbVv8vjauOvrKPOvja93r7qqLecfLCgBt6chBIAZGrC4AWIips0l4qJtXPN3maeXpufWP2+O+Yv3tcdzfl2maZnwfVeo9fLuJn6ekXmfitrhfXbuf5td3arovk3puy5zi38Pz8/GPTdzux2TTbLp/7tvtp5+eWjareDlsOgBsSkcOAjEwYnUBoC7YmE3Cg81LP33ZFWKVzS/1XJra9TNmbfbY+tjjeD5iz+11Yu125dPa/evtZ9xuz8WmNfH9U+L2+LE99+vVSm3+SrNNF//c+qqszR6L9a3j15P1VWm6sTbPT7PH9lpj0+yx9Zf4sT1Xf3uusnnadM/6AMCmdOQgEAMjVhcAUoHB2yQ8xKHEStPFnsf8dN/fWLv18Xz/VB+bFrfV9atbH/GyealpTdb1j9vjx/bcHtdVSl0//1j0OP4c1rF52Hz8YxO3p97DT/f9JX5sz+PPzdp8H5OaBgBt6MhBIAZGrC4AxEEitkl4uO28/HT9jEOStVsfz/f3fexxqk38Y/H94zax6VZealqTuvlIqq3uvf20VMXi6f55qs3WXcq69STxPMVP08+697B+1teknvt+8XPxjyVuB4C2dOQgEAMjVhcA6oKN2SQ8rJuXtav0OH4uTe1+etzmX+sfx32NtRlrb3vLhOenWf917DUqe03dL9X59/VtqVsmVDafmKb5fn5+/rFY3zp168nGJHG7PVdZu/WNxX1N6rnvZ4/tPe19Pd8fADahIweBGBixugCQCgzeJuFh3byMzTM1bz23+cTtqen6qen22KZL3K+uTeqeW9W9h/hpqfYm1n/d6+ra/Wutve5z8OtP6h6LHtsyN7HXWcWv8W3+uT2ue4+6Zaib5uej51b23PNtALAJHTkIxAB6p6DSJogBALBtBGIAW0EgBgDkikAMAACASSMQAwAAYNIIxAAAAJg0AjEAAAAmjUAMAACASSMQAwAAYNIIxAAAAJg0AjEAAAAmjUAMAACASSMQAwAAYNIIxAAAAJg0AjEAAAAmjUAMAACASSMQAwAAYNIIxAAAAJi0YgPxzs4ORVEURVEUlWnlJKtA/MEHHyyrjrU39TG5rWgAAACsEIgbNP2Lwdp8NVnXDgAAgGHkltMGD8S62utDbmoF2XS7MvzkyZPavsbaVffv36+mrthVZs0HAAAA29WU4YYweCD2LMDGUtObpt212tySAQAAgNtR3spJUYHYs/a4n3+cujodFwAAALqVW8bSaIoNxHZrhL/i66fpVgrrZ/NrKj8fAAAA3I5yVU5GFYitzQfYOk1t69i82xYAAADayy0/aTRZBmILvSa+irvuaq1/7absynFT+fH5aQAAAGhmGSoXGk02gbhLXa9oC73rCgAAAM1yy0wE4g3UXTlOTRddMY5Lbfqpr3zTTwAAgKmxrJQLAvEtWOhdVzGbpp8WjgEAAKYmtwyk0RCIN6R5+7IrvfF0L26LCwAAYCpyyz7FBWKF021cffVhNq42dJuFjdN+2mMAAICStc1L21JcIDZ9r2gLsG2qTqovgRgAAJROmScnBOIO6Bfk4kBrz/30prBrfeL+Ta8BAAAYI2WdnBCIe2LBNlV1Un1VAAAAJckt3xCIe+RDbVx1V35TfVVxGwAAwFjllmUIxFvgg6yvptshrF2lx8amt5kHAABAjny2yQGBeIssxDbVupCcKgAAgDHJLb8QiLfMX931bJpKfazqWF99fRsAIPYynM9/tDhO7oWj08vVpPN5OFgcN3ePThet8kWYH+xeH09XdS8cPP48nF8tOyS8CM/n74XZ/nE4u7oKl2fzcLg3W71272GYn11U/RaunoXj/aptWT8K83O98+J1z34eDmaLabMH4fiZXvNtODt+J8wOT4KbQ4Le85fh6OBeNc/FeI9+Gc4uawb82jK/cnV2HPZn74X58xfVlLtZzm9nNxzMv6imvG7Vx9bHog7m4VwNl8/C/HC/mr4fDufPQvWpve7qd2H+4I2wf/xssTYqtq5tfglX55+Hx7bebnxWL8L505+tPo+dWdg7nNevz42sPtNXn3tCi+VOrdeuP7shaJlzQiDOxGpnWJVpWgbfv6kfAEzTBoF49yicLidUYde/JnZxEg5nsyqMfRlODt8IO8tw/HU4PXqrelz1Xb5fKiBeLvruLcLvL8Kni9crBH/9fB4e7K4POFfqt3j/vYefLUK7BWsbT0JDILYQuT6Er+P/YdAUiO0ziQPi1WK1Plys93fC8dn/hMvTx2Fv+fjbqt3zfat2HyprA/Fqne8oRH7xf1fh2T6rl6fhaHcnzB7MwxfPFD4b1mdrF+Fs/nCxHDpH1wXidcvdsF47++yGk1t20WgIxBmwYOvH3WYZmq4iA8B03SUQtw1j1ev3HofTy69WgXj2MJxcKEpZXzu23wsHx7+prv7FgfiT8NnR22Hv6OlrVwdvanHFMdYUiK9Doo3ZqUKiPzfVvq/63jsIjx4dLJa3KRBX/4Cw+V1fHbfP6q3FZ/VVFQzfCIcnX65edoP/R4ieaxneDgePPlxd4W24Qnzt8mk4WoRMBeDnNxZ7EUCX730vPJj/bvHs9l6eHoV7Bx+GR8sr0nWf15rlblyvDZ/dSGgbyElxgdhuNchtRW/i+mBRVZM2fQBgeixs3Dyeql4LxL59dhCOPjurCaZxIPVX8Gwer9qWgXj539oX1essSNuVXb3fg/Dxp4/C/uxvw/GnP1ldUdz7MJycp64UVyHoOsC30BiIbR3V/QNgMwqBuy0C8TKIvqxucbBge+PWAVXNfOpujbAAvzYQ22eeCL3VulpeRe7kVoTq82r6B0yL5U6v124/uyFoeXNSXCA2ua3oTbzaMV5VSps+ADBNFhhaXiF+oftS77mrlilNAacKyzVX7FahJnUrhkLiX4T9jz8JH+/vVj/v1YTKrq8QJ9aR2eQKcWV9IPbqw/3qntmaK8R1wbd1IBZbj4kwaYHb3/piLDBHlV630iIQO3XL3RyIG27vyZzWXU4IxBmyK9y+9MtzdvXb03TfL24HgGnaMBBrwvL+4MWxdHkLROq/oeNAWv33vULw1/+9DNSv/hve2nS18f8tgpFup4ivPFb/Ra/3u/jtIoitC8SLV9TcQ1x7u0WrQLxBwG6wNhBX63e5ji78bQt2e4nC4PPVbSt1V2lvfYXYfVYX1e0tFohtXLoft7qdIhmIN7YuELdb7uZA3M1nNwRllpwQiDPlQ26qTCo8AwBuEYiv7yGuC5gWYF7N8+r8s/CwumVidvCz8NTd6nDjWw1mB+Hx0/Ob/0W//LaEveq/7l+E85MP19wyIfFtGvG3TETLfWOZ43VSf5X2NpLB7cb7+29ziNbX1fNw8rC6dSC1rq5VwTYeczIQ3/x848/j1a0x8bgeh8/8t4XcWioQR59Bi+VOB+JuP7shaJlzQiDO2HIHaShTNx0A0LHlFcTdDr6FIAPLq627LX6ZLyfVVfUR3zvbiVF+djflllcIxCORuhIc3x5h01JtAIAu+O8hriaN1Gi/yzb1PcQTw/cQd49APCJaprgs+NZNBwAAyI2ySk4GD8RtfynMrnyu62fUpzTxOqirVD9NUz158qSaGwAAwDCUTXIyaCC2sGbsebyS4mk+8NVpahs7W3ZVHH7j9nia+gMAAAzJ8kkuNJpBA3Ec0Cy4eW2neU1tJYkDsV/ueLqKQAxgGhLfMpGl6psQWn1/bt9yW2fumzdu/KU/aWi78c0Nie+VrvvqNmyVPp+caDTZB2ILffppVdfPt0+FrQsrLX98K4pN94/j5wBQDgLx5vpfZ1fnp+Hfjg/DXpvlXX4/8CzsH/82fL38ujv3zRK1bfbVeHr+xeor2vwvQPq/DEcgHpQ+g5yMIhAba/NBrk5TW2lsXfh14tdRXYn/SSgGUI443N38rtmdvYdh7r9r9vI34bj6jtrZuwfh3UW/9B+zWKi+W3c5H/vLYtGf4L3xHbvL/rNFCHy3uqK5Hx6ePK++IeFVIH6+/KMb8ZVQY8vzRtjbW/TXfGq/r9j+al71LQTVH5tY/uEJNdeONV5nPqwnwrJbZ83fHXwRzk4+CUfLvvvh8Pj/hNPa71l+ZfX9u9X7Ldfhq+/irW/z389rY7bvAVbb2+Hg0Yer7YBAPChtNznRaAYNxLqSaeqCrqZbiX4xTH2aAlxuK3rbtI78erP1mqqmPprOL+IBGJ+bAW71Z3GrsLn82q5FOLv+M8v2F+jeWvT9qvqe2/WB+Dpg3uD/+lj1J3itv/4q28v4TwNb6PynMF+EtdVfoFu+KmLLc2/5hzxeLsNz3Rh018DqL9q9uoKqZfu6ajXxWDcJxP4vv31b/ZW1pj9bvTinbPhVdd0H4spGf+YZfVHGyMmggVjiAGYryAKaxO1WTda1T1G8/taVvUafBQCMiw9wF1XwszAXB6Xor35VgckC8XWgUylEReFs6eo8nP7bp+H4+sqra7/RvwqZ139hrHpezf/Vn36OxWP2YTUxRgus+z8JR38X3TZQO9Y49DYF4pvjXpW1xXSFeF6935BXiCsE4ixom8mJRjNoII6vTBofiE2qX502fabIr0NfTW2+AGAcbga45BXivcfhdPknj+0Kse47/Z+WV4hd4L2+0qqrt/9dXZF17W0C8f7H4fSp3jd1JVdseVZXiK+W99DWXyHWmGw5rl9TTa8fa03oXa6nrxZB8y3X5q8Qt7/su7yH+NOjcLAI/mvDaB/3EAuBOAu5ZQqNZtBA3BfC2+bqfhHP/nHi//Gix9xKASBfcbi7CGefPe7wHmIfiBX0PgsP92bu9Qpr1V9SaxOIFc5eC+req+U5ONhbvY+/TznFvk0hCq31Y43Xmf8mh92wt7cIl9dtms/n4bHdQ6x/bDz+vOZ2j7biddPTt0wQiLOgzycnBGLcsDqwtSuFYgAYPwuCq6uMr+6/zelPA9sYo//+B0ZKOSInBGLc4K8CW9kvPuqx2q2PXVEGgNFr+paILBCIUZbc8gOBGEl2UrDy4ra4HQAAoElu2aG4QExI64Zfj7681NXkuA8AAEAst7xQXCA2BLO7qwu8dtuEbpmwx3EbAABAHWWGnBCIsZaF3VSZVJsVAACAl1s+IBBjLf9X73zQtfJt+mm/hGfTrQAAAESZIScEYmzMgnBcMZtm7YRiAAAgqdwwJAIxbkXhtu4PeVi7yqb5xwAAYNqUCXJCIMadaD3H5UNvql1lbQAAYHpyywAEYtyJBdy4Yqk+KgAAMD25ZQACMe7M3xLhK749Iv6aNv8aAAAwHbmd+4sLxBawCFnD8Ou/7jOI+1gBAIBpyO28X1wgNgSs4fiQq4qvFHtqt1/Oa+oHAADKofN+TgjE6Jy/FcKqTtt+AACgHLmd8wnE6FwqEDd9Hm36AACAcuR2zicQozc+6DZ9HvaX8Kwft04AAFC2plwwBAIxemMB16ou6G5yiwUAABi/3M71BGL0xgdcq3WhWD/tsV059tP8POwnAAAYF53PczJ4IPZBZ93KadtP2vRB//xn5itlXR+bpp+23QAAgPHJ7Ryu0QwaiLVC4oql+ljVaWrDdsWf2W0+m/j1/h9SAABgXHI7f2s0gwVirQx9B62pCzltp+n1VnEbhuU/W1+3ZX/1TvOwzxwAAIzDXTJAHzSaQQNxHGTqgpJN99VkXTu2L/787voZ2eu7mBcAANie3M7bGk32gTi+Euif14nngTzYZ+fLPtNNxL9wt+nrAQDAcHLLaaMIxG2neU1tGJZ9dnW1Kf86gjEAAPm7zfm+TxrNoIHYrxB7Hq+kttO8pjYMyz67utrUXV8PAAC2K7fztUYzWCAW/XKUDzN2hU8//cqy53G/Ov61yJc+x7ptoA3rb9uH/bQCAAD5ye0cPXgg7gthaFx8iLXaVGoeKgAAkJfczs8EYmTBB1gr+2q1Ta4Yi15rr/NXjDedDwAA6IfOyzkhECMbFlytLMBu+lnG81FZMAYAAMPL7ZxMIEZWLMD6z++un6Wf513nBQAA7i6387FGU1Qg9v9NjnGzz9HKPtvb8PO67TwAAEA3dD7OSXGB2OS2orG5OBBb3UYX8wAAAN3I7VxMIEa2/F+j82FWtelV3ng+m74eAAB0R+finBCIMQoWZOtqnVSoBgAAw8jtPEwgxij4IFtX62zaHwAA9CO38zCBGKNitz7Ef91O1eY2CHu9apPXAQCA7uj8mxMCMUbLAq2vdeE29RorAACwHbmddwnEGK34Sq/K/rpdG+pn/e31Nk/9Qh8AAOiHzrk5IRBj9CzMxtVG6nWqtqEaAABsTufanBCIUQQfZn21kXqdCgAA9CO382xxgdj+y5tAMz363ONfttv0Sq9tO7b9bPp6AACwnp1nc1FcIDa5rWhshw+0VrLJ9qC+cTAGAADdye38qtEQiFEUC7KpWnfFV+2q+EozAADoTm7nVgIxiuSDrD2Oq0l8pRkAAHQnt3OrRkMgRtHicGul6XVfr6bpqf4AAODudF7NCYEYk+HDrVVTyFW7adMfAAC048+xORg8EMdX71J8e1x1mtowXfH207SdpPqqAADA3eR2PtVoBgvEFob10wfj+CqctVvZLzzF/bzcVjTyYduZ1TraztTPtr2m7Q4AAKzX5vy7TYMGYgsZXpuQ0rYPUMe2oTbbktT1b/NaAABwU27nT41mVIHYrtKlqM2KoIImto2s29482/as/6avBwAAK7mdOzWaUQXi1GtSclvRyI9ta1absP722jbbJAAAWNn0vNs3jWY0gdjaCMTogm1PvtqKX0cgBgCgvU3OudswaCBWiLAwYY/tub4HNg4Z1t5G236YLr/N+WrLXm8/AQBAO7mdNzWawQKxxKHEpEJG3KdJ236YtlQo3sRdXgsAwFTlds7UaAYNxH0hnKAtheLbXuW119kv26lsfgAAIC23nEYgxuRZkLW6DR+A7zovAABKl9s5kkCMyfMB1mpTqdfbT64WAwBwk50jc6HREIgxaRZifdV91/U6druElc3PngMAAAJx7yyA5LaikT+/7XSxDfnXdzVPAABKkNv5UKPhCjGwEF/VVd3lqq7Nz//C3V3nCQBACXQ+zAmBGIj48NrVdmTz8fMlGAMApqqr82tXCMRAgg+uXfDz8wUAwBTldg4kEAMJPrR2tS3ZLRSan/9pbQAATEVX59auEIiBBG0/cXUlNe9UAQBQqtzOcwRiIMGu4Prqkubv38Me25Xirt8PAICc5HaeIxADNbQN+doWC8eyzfcFAGBbcju/aTQEYqCGtiOrbfFXibf93gAAbENu5zYCMdBA4TS+naFv/v300+rJkydVDwAAxk3ntZwUF4h9gADuym9Pqm2F4vh9t/neAAD0Tee1nBQXiE1uKxrj5AOpSn91bptXiuMCAKAEueU0AjGwhg/EVtum9yQQAwBKMcS5tAmBGGjBgrCvbRrqfQEA6ENu5zMCMdCSD6VW27hqq/fQe+l2jW2+LwAAfdG5LCcEYmADFkjj6jugpt5TBQDAGOV2Dhs8EOurpBQmrJq07SeEBfRB26sPpL76pu0+9b5t9gcAAHKi81dOBg/E8cm9bgW17WfWtQN3tcn22KX4vbb9/gAA3FVu5y2NZrBAHJ/I7XlqJfnp/kpZnaY2oCu2HW5ze/PvqbL9AQCAscjtvKXRDBqI4//utZO856epf91/EVubKp4H0Afb1qzqts2+6P3sl+22/d4AANxWbjltVIE4ribr2oEuxNtkXfXJ5t/3+wAA0JXczlkaTWMg1i8R9UUrY5NA7KWmeU1tQJe0Ddv26Lc7P81P79q23gcAgK7kdr7SaBoDcd3JvgvxPOvep+00r6kN2AbbRn31wf5R2ff7AADQldzOVRrN2lsmdMK1shOu7lu0E/Fd+D82oLJ52nsZ/96+Xx3/WmAom263t5H6Krg+3gcAgK7oXJWTVoHYi0+8VrnJcUyYpnhf6Wvb3MZ7AADQhdzOUxrNRrdMWNkVKHuemxzHhGmyfSRVXbL52by5SgwAyFXX58C70mjWBmJfsbrpQ8ttRWO6mv66naor2g/9fLu6rQkAgK51ef7rwtpAPFa5rWjA+NBq1SWbXxyQAQDIRW7nJY0mGYjtyq//0n9fuZ5gcx8fINo+fWmb7YrfB/y+0Md7AQBwG3ZuykVtILaTZ1PlLPfxARZW4+oysKbmrwIAYEi5nYtqA7HxV5jGhJM+creNQOzF7wMAwFByOw/VBmI7adadtFU5y318gGj/ivexbQXivt4HAIB1dB7KSW0gHrvcVjTQZJtBNQ7gvgjJAIBt0DknJ7WBWCfGdZWz3FY00MSHUv0ia5/ivw5p7L3HsH8DAMbNn39yUBuI/QmzrnKW+/iAWLx/WW1D/H7xcwAAupTb+UWj4ZYJIAM+hPraJn9leIj3BwBMQ27nl9pAbP9tqr+yZY/jyhkncoyN7VfxLQ02Xfti3+y9VH4MAAB0KbdzS20gthNhfGL0lbPcxwfUyWGfs/ey99WYAADoyjbPaW1oNK1umbCrRla5svHltqKBTfj9zEKp1Tb2P9uH4ve1xwAA3EVu55JWgdhOgr62cVK+C40RKEG871ltQ+p9rQAAuK3cziNrA3HqqtAYToi5jw/YhO1zcW2Tvd9Q7w8AKEdu5xCNplUgjuV+MuRkjdLEv2xntS2p2yi28Yt+AIDybPP81YZG0/qWCaPH3DIBbJ/ti762vS/qPe2nPQYAYBO5nT80mmQgtpNdU+Us9/EBtxXvh9sOxKkrxZrmiyvHAIAmOnfkpDYQj11uKxroUhxGh+DHoPLTtjGmX//61+Gbb76pngEAxsTOG7kYPBDrxGkn0aaV4/v4qtPUBoxd2/1gm2wc2xrT22+/Hb773e+Gf/iHfwhfffVVNRUAMAa5nLuMRtMYiOt+kaeLK0AWhvXTB+N43nE/X97vf//7cHZ2tiz1t8cUVWLZ/qL6r//6r/Af//EfyX7bqvfff//GmPT8r//6r5djS/W/a33ve9+7fq/vfOc74d133w2ff/55dTQAAORMx+6crA3ENmA/8K4WQvOJQ62mxfNPTYvpBGn9KIqabr355pvhV7/6VXVkAADkSMfrnGg0rQOxhVf/+C5S89E0e09j03zFr9N/mf7VX/3VdanPfD6nqKIr3i9SfbZdfh9U/fmf/3my311L8/XLPpvNlmH45OSEe4sBIHM6buekVSC2Qdtj1RCB2EtN85ragFLYfrBufxhCPLaux6d7iG2+uj1D/0sEABiHrs8Jd6XRNAZiBVYbtJ18uloIzadNIE5Z16/NPICxs/3AVw5sv/Zj6npsP/7xj8NHH33EL9QBwAjlcr4yGk1jIDY6wfnqguajFWLztJOnHut7TO194n7+eR21A1OQ+sXXodn+q7H86Z/+6fW4/H4NAJiuHM5VXqtAbCczX12d1OykaWVsupfqV6dNH6AE8T6U07YfjyfHMQIAti+384BG0+qWCR+AU2E1N5xwMSXa3n3lQmPRFWIdM1LBXeWPLQCAadDxPyetA3EstwWJ5T4+oEva3n3lQmPRL78ZH37j8eY0bgBAv3I75ms0rW+ZMHqc+1UdTq6YEv+NC1Y50DjiQJwaZzzNCgBQptyO8RpNMhDHJ6ZU5Sz38QFdSgXiHP7RqnH4QGw0Nl82Xv9TpV/CAwCUR8f4nNQGYs9OTlY5G8s4gS6lArHVkPT+qUDcxI/ZwjEAoCy5Hds1msZAbF/p5K/kqHK/csNJFFNigdjvo1aaNhS9/6aB2I41Kv+VckMuBwCgWzqu52RtIE4NeAwnp9xWNNAnC8RGj+tqm/R+mwZiz44zQy4DAKB7uR3LNRoCMTBycSDW/qnnqdJV123R+901EMfj1zRfNh0AMB65Hbc1mrWB2A/anutElLPcVjTQpzgQe7bPxrUNep+7BGKvbvypaQCAvOV2zNZoGgOxvwLjK3djGCPQlaZALH7fjatPmn9XgTjFxr+NZQEAdCe3Y7ZGszYQxzUGnBwxJesCsbHg6KvPfVrz7zMQa+y2DH0vCwCgOzpm52RtIM5twG2NddzAbbQNxGLh0VdfNO9tXCE2fS4LAKA7uR2vNZrGQBx/7ZoVX7sG5GOTQKx9V3192X7dNc277yvEVrYsOmbFy+MfAwCGp+N1TtYGYjvJxJXrCcaPEZiKTQKx+P3EV9c0zz4DsfFjj49NtmyEYgDIRx/nnLvQaBoD8VjltqKBPil0fu9736uetWNB0VfXoVHz3FYg9uXFbXE7AGD7cjsWNwZinRztBDK2qyuc9DAlCp23CZ5+H1d1/R3Fmuc2AnGdePnEfgIAhpPbsbg2EPsTiMTPczemsQJ3pavDtw2etm/76ormNWQgjvWxjACAzeV2HNZoCMTAyGl7v23wjK+idrnv3GVcXav7ZUIAwPbpGJwTjYZADIyctve7Bk/bx7vcd7oYV5f8snW9rACA9nI7/mo0BGJg5LS9dxmIu9p/uhhXl+JlVHGVGAC2T8ffnGg0jYG4qbqg/8bUCcmqjTZ9uxofMAba3rsInn7/troLvT6nQGw0LjuO2GMAwPbc9fzStdpAvC1aIXE12aQfMBXa3vsKxFa3odflGohTBQDYjtyOuRrNYIFYK8N/zZNdralbSdZm/ZqsawdKou29q+Dp90NfqemapqqjPjkGYhMvU2pZmpYPAHA7OubmZPBAHJ9s7MQU89PtJBazPr4vMAXa3vsInvH+5J/7qqO2nAOxxKHYxNN9GwDgbnI7pmo02QfieFpdIPbWtQMl0fa+jeBp+2KqUjR9rIFY7HldOwDgdnI7nmo0ownEqarT1AaURtv7toNnHCTjfVmGGNem4l/steWw6bZs9rjrv+YHAFOk42lOBg/EfoXY83UryU5MTda1AyXR9j5E8LT91So21Li6FC+jCgBwN7kdSzWawQKx6GqLP9HY1Zmm0EsgBm7S9j5E8Iz333i/G2pcfdBxx449KnsOANhcfL4YmkYzaCDuS24rGujTUMHTB0RfFhT1uJRAbFLLDADYTG7HTgIxUABt70MFTwuFvkoNxPFy+gIAtJfbcZNADBRA2/uQwTO+alryFWKxZYx/AgDa0XEzJwRioADa3ocOnhqDL5tWYiCWeHkJxADQno6bOSkuEOukZFdsgKnQ9p5D8LRw6EvjKjks2jFHv2Boxx5VycsMAHel42ROigvEJrcVDfRJ2/s777xTPRuOhcG6KjEk+uWLn9s0AMBNuR0fCcRAAbS9//CHP6yeDcuCYKpKv2qaWmYrAMAruR0XCcRAAbS95xKIxYKvhUGrKfyVNy2nlt/KLz8AYCW3YyKBGCiAtvecArHRuHQPsX6magqmutwA0CS3YyGBGCiAtvecA3F8pTSu0vlfuPM/7S/96bHopxUAlCy3Yz+BGCiAtvecA7FR0NO0uipZalkt+MbLTiAGULr4uDc0jYZADIyctvcxBGKj6amamrrlJxADKF1ux3wCMVAAbe9jCsSi0Je6YozVemNdAChZbsc4AjFQAG3vYwvERn1SNVWsBwBTkNvxrbhA7K86AVOh7X2sgVjUL64p3zZgy1+3Puw4N+V1BGDcdFzLSXGB2OS2ooE+aXsfcyA26h/XFKXWQ1y+nxc/B4Ac5Xas0mgIxMDIaXsvIRDHV0WtpkrLbleC7XE8TZX6Wjex6WP2zTffVI8AlMSOU7kgEAMF0PZeQiA2el1cuMmvGx+OreI+fvpYnJ2dhT/7sz8jFAMFyu14pNEQiIGR0/ZeUiAWvbapxn7ls29aRyZed74tZ2+++eZyrB999FE1BUApcjsOEYiBAmh7Ly0Q+6ueqSuguh0A9bTOrGyd2WP/F/JUOfqXf/mX8J3vfOd67L///e+rFgAl0H6dEwIxUABt76UF4hTNzxc2Y+vNh2SrnCj8xuP7wQ9+ULUCKEFux53BA7FdqbCqu1oRH8DXXdlQH2AqtL1PIRDHxwFsxo6b8XHXr8+m4+q2KPzGY5vNZuE///M/qx4Axs6OObkYNBDbgc7Y83glpaan+nlNbUBptL1PIRCL7ftWuL14/eWwXj///PMb4/C1v79f9QIwdtqnc6LRDBqI46sRduDzNp2WagNKpu19qoHYCptLrUe7Cu/Fz7flH//xH5fvrW+bSHsRzp/+LBzMqvHvPQzzs4uq7Spcns3D4d5s2TY7+Hl4dnm1mv7s56vXzB6E42fq/204O34nzA5Pgr0aQL+GOq7U0WiyD8Setade6zXNAyiNtvepBGILbHE1HQ/QjtahfXexrVP9FJvuS22a3pe1gfjiJBwugu0yyF49C8f7i/B7MA/nart8Go4WYVhtX58dh/2dWdg/fqY4HE6P9hbTfxE+PXxj1f58Hh7svhfmz18sZwugf3ZsycXoArFZ16/NPIBSaHv/6U9/Wj3Lh8bVdSA2Fsh84e7ideorpmnxMbxL668QO1UAtkB8tQzBb4TDky9X7dfiQPxJ+Ozo7bB39HTRAmBbUseUIWk0gwZif3XBn+A8m+YPvKl+XlMbUBpt7woPudG4+grET548uT4OWGF7tL51TLbjdh9aB+Kr5+Hk4f6i76sA/PL0KOxW24VqdvCz8PRcV4Bv3jLx8aePwv7sb8Pxpz8Je+q792E4WfYD0Ke+jhu3pdEMFojFDla+JD7Ixn18W8q6dqAU+ite2t6nFojFjgW+sF11FzK60CoQX4fhe+Hg+DfXV3lXgXh1m8RL3RKxCMC7R6fhZdW+8mU4OfyLsP/xJ+Hj/d3q52I+8y+qdgB9ye14rdEMGoj9wdSvnNRVh1S/Om36ACVQWND2TiBud2xAt3Sslj7W/fpA/HU4PXpr0edmGF5a3l88W90KUd1rfDMQX4XL08dhb+9xOL34bTgmEANbldvxWqMZNBD3hRMjpmLKgTj+B7WFM2yP/wz02D6DLj6LtYG4Crr2/suyX6qLvoHi1S0TlavfhfmDvfBg/rtFNF70PfmQWyaALdJ+mRMCMTByUw7EHvv8cGzd66eVBeW7WH+FGMBY3fX40DWNhkAMjNjUA7Hewxe2S7/caOHXfqrir2/zj9siEAPl0r6dEwIxMHIE4puBeJPAhe7En4Mvo8cWjG163McjEAPlqtvvh6LRFBWI7eCa24oG+kIgfrXPWyE/9rn4QOzL/iGTavMFoAy57c8aDVeIgRGbeiCWdSELw9NnodKtFPbZ+M8q9Rfv/BVie70VgHHTvp0TAjEwcgTiFb1XqjBePhDbZ8nnCpQht/1YoyEQAyNGIL4pvvLI1cTxskD8/vvvX18Z9p9t6qoygHHQPpwTAjEwcgTim+LQZIXx8VeIJf5MVV7ddAD5yW0/1WgIxMCIEYhvqgvEKoxLHIjFf5b2Wcf4rIH85bafajQEYmDECMSvawrFVuqDvKUCsT63uDw9t88YI3Q+DwfV53dds4Pw+Ol5uFL7y9NwtBu1q3aPwumrv8udtu611++9W/357m/D2fE7Vb8fhfl59QY187n5p8GxjtZZTgjEwMgRiJtpDE2FfKUC8Tqpz9ZPi9uQmSqUXofL5Z/YvpcIvF+E+cFubRB+eXoUdnf2wtHpZTXFq3mtC+Ozw5NwEb4MJ4dvVNuMC8Te5W/C8cFifLP3wvw5f/J7E7nthxoNgRgYMQJxO/qLaqsT283SdOTptoHYrhzrcUo83W8D8RVnbFldIN4/DmfLS8Sm30C8M3sYTr74LBzO7FiRCsRfh9OjtxZt++HhyfPVFWy0Vrd/DqW4QLzacFcFTAGBeDP+GOEL+blNIF7HPmv/2acKA/GhtKrZwePw2dlF1cHUhNrk7QxxmG0KxLvh3cO/Dfs774R/Ov7JIlS/FQ4PddtEPI8X4fn8vTDbmYW9o6chFbvRTJ9NTjQarhADI0Yg3tzqJHmzkJ++A7H9tKvCcZuJn0tdX9yRu0L84vk8PJgpEP88PLuMr7/2dYV4Nxx88smrUL37v8L8kx8tHvtAfBUun/08HGhsD+bhOZeGbyW3fUejIRADI2aB+OOPP66m5EPjyjEQ+/9S92XTkYeuA7FujbDPuK5sO6j7qdL3H9s0Px0dcIH45SJ4Xpw8rLkK22Mgnp9e3zs8O/xleDaPAvHl03C0Nws7e4/D6WtBHW1p/eaEQAyMnAXi+XxeTcmHxpVjIDYaX11heH1cIW4SbwM+9Fql+sWFO7gRiBfsHuKdtxbh9utll5XmQNxsXSD+78VDheA3wuHJefXYAvHL6vnrn/v1mNGK1llONBoCMTBiBOK7SYUeFX8FbXjbDsSbsO3G/9Q2Y9uP365k3fZk/Y3v799D1UY8v5R4vlb8oim2Yd32uW0aDYEYGDECcTc01lRhODkH4hQLmG3LpNriatPPS7X7atNHBfQlt+1LoyEQAyNGIO6WxtxUCj3YjrEFYo3Vftpj8dNT4r6+f/zYQncT3163vdp0m6+9Rj/9a/y8gC7ltm1pNIMGYv9fTPGO6NlBYF0/oz7AFBCIu+WPNXacsee+1h2DcHdjvEK8rlJS/dZVE9+v7vaHdb9gKH5bt2lAV7Rt5WTQQGw7m7Hn8UpKTU/185ragJIQiPtnx5tUoT9jC8Ql8ds22zr6kNs2pdEMGojjf3WmdrzUv06b+qniNqBUBOLt8McWX5qGfhCIh2Pbu9/m/XPfbgVsQttRTkYRiGN6zbo+ua1ooC8E4u2y40/bwu0RiPOQ2qbtp4mfA+vkts1oNKMJxHYiil+TktuKBvpCIN4u3Xup5bKqO4bFhc0RiIen7buujL8fuW5btzaV7UM23Uq/U+TnYY9T90FbW6r/NvhlrmPtTX2M+vjlUKWW2/j+OVj3tYIpOY1fNJrs7yGWuul1NukLjBmBOC92rGpTaEYgHgcLfPH2fdvadF5t+hsLknXlpdp9teljJW3eOzU9Lh+G47a4TKrNl5dqt7LPWlLtm9i0f980msECscQr01ZQ2w+8TlMbUBICcZ7sGGWVmmbTkUYgHofU+dqLp1mo8tOsj02L2zzfz967qX8f4mAYi6c1jaluXn66t+69t83GsOlYchi7p9EMGoj9fzv4D9mmi2+Pq05uKxroC4E4X/GxSusjrqbj2NQRiMfBb+dWXqp90/JS7XH1bd37xe2pPibOQb5S6nLTUG47Fu3bORk8EPcltxUN9IVAPE5aN6nCKwRioFy5He8IxMDIEYjHSeumrrBCIAbKlduxjkAMjByBeNy0juLK4b9Bc0AgBsqlfTsnBGJg5AjE46f1FBcIxEDJcjvOFReI7cZuTiiYCgLx+NkxKy47nsU1FQRioFzat3NSXCA2ua1ooC8E4nJofVnFfFuqSkQgBsqV23GLQAyMHIG4LHVXgbUurYyfpirtCjKBGCiX9u2cEIiBkbNA/Otf/7qakg+Ni0DcH63fuioBgRgoV27HKQIxMHIWiHMMDRoXgbhfWsd1NfarxQRioFzat3NCIAZGTleGcw0NGheBeDu0rutqrAjEQLlyOzYRiIGR073DuYYGjYtAvH1a720qd20C8dXZcdjf2Q0H8y+qKfIinJ98GPaWy3kvHBz/Jlwup1+Fy2c/DwezxfTZg3D87GIx7dtwdvxOmB2eBD0DsB25HYMIxMDIEYiRonVv5fnpqvgX8Z48eXI9behbLpoD8SLcns3D4d5s0ScKxBcn4XA2C/vHvw1fnzwMs513wvHZt4uGy3B6tLcIv78Inx6+sQzBXz+fhwe774X58xer1wLYCu3bOSEQAyNHIMYm9Jncpvxrt6UxEL88DUf3DsKjRweLwHszEL88PQq7O3vh6PQyhPN5OLhujwPxJ+Gzo7fD3tHT6goygG3Z5rGkDQIxMHIEYmxKn0uqRFeFU21xbUObWyZW4bdtIL55y8THnz4K+7O/Dcef/mR1e8Xeh+HknCvFwDZs6zjSVnGB2P6bL7cVDfSFQIzbsGOlL/G3TOjza1v2+i51H4i9L8PJ4V+E/Y8/CR/v71Y/7yX6AeiD9u2cFBeITW4rGugLgRh90ee3SXXttoG4/h5icxUuTx+Hvb3H4fTit+GYQAxsXR/HjLsgEAMjRyDGNtnV49RV5Lrpt3XrQFz7LROVq9+F+YO98GD+u0U0dn25ZQLYmrscG/pAIAZGjkCMIekztvL89LitrTaBGMA43fa40BcCMTByBGLkSJ+9r9sgEAPluu1xoS8EYmDkCMTI0f3795efvy9/S4Xnp/s2AjFQLu3bOckmEPuDZpuVtK5fm3kAJSAQI0cKtnac3rQMgRgol9/Xc6DRDBqI9RU/dhC0qwN6rKsLKb5P08psagNKQiBGrppCsdpMql31/e9/f/nz/ffff+3Yr9J5ws8HwHhoH87J4IHYDnCxuhVlB0KrOk1tQEkIxChBHHZVqSvEcR9f66Reo4pDtW8D0I/c9i+NZlSB2KQOVjYt1QaUikCMUvjjt2rTQNx3AehObvuURlNMIPZyW9FAXwjEKNW6e4jV5iu+0uulrkBbxbfo+bb4uc2n6b0ArGf7Vy40GgIxMGIEYpQqh1+q0/u3KQCbyW2/0Wiy/6U6m+7Za+o0tQElIRCjVDkEYjsnWfnncZvOZ1k4n4cDN65lzQ7C46fn4UrtL0/D0W7Urto9Cqcvl3OIvAjnp78Ih3uzqu8s7B3+Ipxu8lf9qjHtHp2G5FtgcrQt5WTwQGxu7JTRSmo7zWtqA0pCIEapcgjETTQ2X/GFm8HE4XP5p6rvJQLvF2F+sNsQhFeuns/Dg9kiBD/8LJwrUV/+JhwfLOa39zicXi4j9noEYkS0z+REo8kiEHcttxUN9IVAjFIRiG+pLhDvH4ezG/m1TSD+NpwdvxN2Zg/DycWrF788PQq7O2+Ew5MvqynVvPbeDQfLK8kuQIsf09WzcLw/C7PDk3ARrsLFycMwuzEvTIH2mZwQiIGRyzk0aFwEYtxW7oFYND6r3AKxH9vs4HH47Oyi6mDaBOLLcHq093qf5XvshoP5F9WEal6z98L8+cUqRO+8E47Pvl013wjpFrLV93k4OXxjs6vNKIK2y5wQiIGRIxCjVATiW3Lh88XydgcF4p+HZ68Fzh6uEB/Mw/ki8p7Pf7RYJ3vh6PRy1XwjEC9cnITD2SzsP3oU/k4/j5+t7m/GZGifyQmBGBg5AjFKNYZAbBSG87xlwm5JmIW9o6ehiqeVNoH49XuIr84/D49fu4d4w0AcvlxdGV5Mu3ElGZORW04rLhCvdq5VAVNAIEapxhKI7Zyjip+nqndx+LR7iHfeWgTUr5ddVtoF4sUMwuXZL8ORQvByGVLfMrFpILagvpjfa/c2Ywq2si9soLhAbHJb0UBfCMQo1RgDsa4S++epgixC9unjsMcv001WbvsCgRgYOQIxSsUV4lJVv6i3WBfpe5sxBbntCwRiYOQIxCjVWAJxG/GV43U26QuMUW7bNoEYGDkCMUpVciC2X8Krq7ivfgIlyW2bJhADI0cgRqm4Qvyqb5vXAGOS2zat0RCIgREjEKNUJQXiu7AwrZ8pml7Xlgsb41DjtPd+8uRJNQVDyy2nEYiBkSMQo1QE4tU+5CsOlHF7rvwYtx2K/XurkIfcPgsCMTByBGKUikD8epij7l7IQ26fRXGB2P5bhI0eU0EgRqkIxK9ul7CK/8vft2/7yusmmpahb34d3b9/v5qKoenzyElxgdjktqKBvhCIUSoCMVAuAvGWEIgxqKtn4Xh/Vv0Z08rVeXj6+GD1p0qXf/p0Hs6avpA+NY+EMQfiq7PjsL+zGw7mX1RTHPtzs7V/VlZ/TnYeDvcW62jxPnzBf3kIxEC5cstpBGKga5fPwvxwf7kNvgqz9nf7V3+mtDEISnIeaeMMxD7MptbDi/B8/t7qHw91gfjyaThavH52eBK+Xq7PWdg/fraYM0pBIAbKpX07JwRioFP6k6Rvh4NHH4aDWV2Ytb/hXxeI28zjlVEG4pen4ejeQXj0SFfME+vh4iQcatkXr68LxKt/VKz+gYEyEYiBcuWW0wjEQB8U+HbTYfbq/LPwUFdGZw/DyUXD9cyGeXgWGr755ptqSj40rqZbJl6eHoXd1wLx18t/EOwd/e9wfLBbG4hXr61C86JmBz8LT89fVK0oAYEYKJf27ZwQiIE+1ITZV2H4QTh+dlFNrbFhIM6RxrVZIK6unu89DqeXvwvztYF4dZvEy+fz8GC2E3aPTkPydmOMEoEYKBeBOKKvX9FXolg1adtPCMQYVCrMVve8tgrD0jIQ//SnPy0oEL8M5/MfLV93o1LrYHlbxSzsHT0Nl9UtFgTishCIgXJp387J4IH4xkmvqpS2/cy6dqBXr4VZ+6U6vw27IHg+DweLaTcCXctA/MMf/jDb7V3j2vyWCfNFdIXYwvJeODq9XDx/Ec6f/mx1n/XifbhlojwEYqBcuZ23NJrBArFWhl8h9jxeSfF0XSFO9fOa2oCSjDkQA00IxEC5cjtvaTSDBuL49gdNi1dS22n+loq4DSjJr371q2XQVH33u99dbu8Kxqq/+Zu/qXoN45//+Z+vx6JxaXz2XG1AWwRioFy55TSNpphA7DW1AWOnb5SwIBzXRx99VPUahsJLalwqgg02QSAGyqV9OycaDYEYGKF//dd/DX/0R390vS+o/uRP/iSLr1+zq8O+fvzjH1etQDsEYqBc2rdzotFwDzEwUm+++eb1vjCbzcLJyUnVMqyvvvrqelwqXc3O8XuSkTcCMVAu7ds50WgGC8TiT5pWEt8HHPfxbSnr2oESKCj8wR/8wXJ7/8EPflBNzYNu3dC4dBX73//936upQHsEYqBcueU0jWbQQFz3PcQ23Uv1q+P73r9//8bzu5Q+wNT0u1Qf8+xymVVjWO7c56fqY55//Md/vJzv4eFhsn2T6nK7+fu///vwh3/4h6NYj1Mc4xiW+fvf//5ynu+//36yfdPq+rioGsN6nOIYp/hZj3GZczJ4IN6GLle6Psiu9THPrje0MSx37vOTPuapIKxvnehC19vN559/PsltR3If4xiWWbcA/eVf/mVnt9v0cQKe4rYjuY9xip/1VLfvrmhUBOIN9LHBjWGeYxjjGA6ouc9T/zPTtT6WeYqfNdv33bF9d6freXa9zFP8rKe6fXdFoyIQF2iKy5zrTtY3PutpYPueDrbv6eCzzodGRSAuECeR6eCznga27+lg+54OPut8aFTFB2IAAACgDoEYAAAAk0YgBgAAwKQRiAEAADBpBGIAAABMGoEYAAAAk0YgBgAAwKQVHYj1/ZVWUzOl5fafcx9/qScnqc9Vy+zXQYlSy1byMtctW8mfdZvlatNnbOqWaYqf9VS379KP4ally3GZiw3E+uLnuKZiKsvslzOuUqWWzy93qr0E8XL5ZY3bxq5p2ZraxqzNcq1rH6N4mWy5UtOtxi61TKq6thKklktlmtrGTmE3tVx+Wtw2FI2guEBsK9f+1aF/ieSywvvml7305U19pqUuty1rvMx6fP/+/erZStxnzGxZ/DLZZ6z92p5bjZ0tpy2b2DSV/6xtPajGzJYhtczGP4/bxsqWo+6zjrdnmz5mtgxttm+x6WNmy+A/T79cmh7v11YlsOX0y6yfOR7L9O7FBmIvh5XdN7+MtoGVzpbZV8naLGOJ68Evkz3O5SDaN1tGW2av1OX3yxUfy0pdZvHLZo99lcLvu03LVdpyp5ZZj9uuj7GxZbPHtmx+uvHtQ9G7E4gLEC9ffBIplS23r5KtW8ZS14FfLnscV4n8sulnjieRrsXLFC9ficssqeWOqxRxAEwtW930MfPLa8sWT7Mau3g5/HP9JBBvSWrF5rCy+2TLl6pSpZav9H8IpJZZ//2oaVr2+CBTCr/cqXWQmjZm+u/E+PPU8sWfb0nLnVpmsWVMVQmm9Fk3fb5S4rFs3TLb8nq+faxsGeoqx2XWuxcbiG3lasXnsLK3yZa5ZKnPtPTlTi1zyctr/HLXrYN42lhpOeKThcTLaM/9tLHSMqSWOaWUZZa65U5NL2G5bRn8svnlGvvypdjy+WXzz/WzxM86Fi+zXz577qcNQe9eXCAWbWB+JacOOiWz5S9d/Dn7G/VLZMtp/LLHVZJ4mUrdv/0yxSXavv20EpbbL09cKU1tY+KXMy4p8bOWun3XT4tr7OqW2ZT6WXu2bCbHZdboigzEAAAAQBsEYgAAAEwagRgAAACTRiAGAADApBGIAQAAMGkEYgAAAEwagRgAAACTRiAGAADApBGIAQAAMGkEYgAAAEwagRgAAACTRiAGAADApBGIAQAAMGkEYgAAAEwagRgAAACTRiAGJmhnZ6exfJ9tGuI9t63PZexi3vHr+xyv98EHH2zlfVL8+952efUaLQOAcdJeTyAGJsZO+nXl+2xL/P6l6nMZu5h3/Po+x+sNGSb98t1leQnEwHhprycQAxOXCgE6udsJ3v/00588eXLjufHT47YU9bcx+NfZfDzf7tvseWpM8fMm1te/t02zMv55qt346U3r2krv7afHj8Wep6b5x23K6LF9BibVx1fTWO15G7ZOUvMx9txPM77Nt/vnde1+mf3nU9c/nmbsdQDGR3svgRiYOB8CjJ9mj9eVaWpLUbhIvcbKpNpUTW1xrZN6TarW9TWpNpVJtama2uKycGbP/eO2Fb/G1LX7ampTraM+8TK0KZNqUzW1qeL2+HnbMrYdAxgf7bkEYmDi4hO7+GlNbRL3vX///jIcWMX9U+J5qOzqo9g0C07i521l4ufWdx17XXzl00rLZvOxvppubJp/7Ofl2+25f73Ye/i+Yv09//q4v/j31OO44tfEr/evtZ9ePFbfbtPW8a+LX2Pv6/k+9ti/r9a3TU+12zQTP67r79t8GT1WO4Dx0Z5LIAYmzk70np/W1CZx37pq4vuk+qemiU2P2+PnbcNK3Xxsmp+Pn278tHXtdWOy6b6vpPrruabb41R/P63Nc8/aNx2rpKalqM+6ZfB8n7i/semp9nha/LhNf1+mbh0ByJ/2XAIxMHHxiV38tKY2iftauNlEPA97bGyan+6n1bWZtmFlk/nEbeKn2WNbH/bc2m1e9tz4fr4ttQx6Hs/fxM/F95fUazxr33SskpqWoj51y1C3zDbNHvs+fqxxm8TT4sd1/eO2+HlqrADGQXsugRiYuPjELn5aU5vEz1P/jW6Bp46fh3/spYKOzdeem/h527BS9zqr1C0TXjzNv94/NvH8VXoPsecmtQx6run22NrtcVOlxtP0fJOxSmpaivqklkHqljnVx1fd/CSe5p/HbWLTmt5HUmMFMA7acwnEAIBBlRAkCcPAeBGIAQCDsyvNY1bCMgBTRSAGAAxu7LcbxLdPABgXAjEAAAAmjUAMAACASSMQAwAAYNIIxAAAAJg0AjEAAAAmLIT/D52ID+2fCwjyAAAAAElFTkSuQmCC" /></p><p><em>Figure 1 Kaplan-Meier curves for overall survival (intent-to-treat population)</em></p><p>The results from the trial were not consistent in the subgroup of patients with a poor performance status (WHO PS=2, n=70), where overall survival and time to progression were similar in both arms. However, no unacceptable risks appear to be present in this patient group.</p><p><em><u>Recurrent or progressive malignant glioma</u></em></p><p>Data on clinical efficacy in patients with glioblastoma multiforme (Karnofsky performance status [KPS] &ge; 70), progressive or recurrent after surgery and RT, were based on two clinical trials with oral Lagona. One was a non-comparative trial in 138 patients (29 % received prior chemotherapy), and the other was a randomised active-controlled trial of Lagona <em>vs</em>&nbsp;procarbazine in a total of 225 patients (67 % received prior treatment with nitrosourea based chemotherapy). In both trials, the primary endpoint was progression-free survival (PFS) defined by MRI scans or neurological worsening. In the non-comparative trial, the PFS at 6 months was 19 %, the median progression-free survival was 2.1 months, and the median overall survival 5.4 months. The objective response rate (ORR) based on MRI scans was 8 %.</p><p>In the randomised active-controlled trial, the PFS at 6 months was significantly greater for Lagona than for procarbazine (21 %<em>vs</em>&nbsp;8 %, respectively &ndash; chi-square p = 0.008) with median PFS of 2.89 and 1.88 months respectively (log rank p = 0.0063). The median survival was 7.34 and 5.66 months for Lagona and procarbazine, respectively (log rank p = 0.33). At 6 months, the fraction of surviving patients was significantly higher in the Lagona arm (60 %) compared with the procarbazine arm (44 %) (chi-square p = 0.019). In patients with prior chemotherapy a benefit was indicated in those with a KPS &ge; 80.</p><p>Data on time to worsening of neurological status favoured Lagona over procarbazine as did data on time to worsening of performance status (decrease to a KPS of &lt; 70 or a decrease by at least 30 points). The median times to progression in these endpoints ranged from 0.7 to 2.1 months longer for Lagona than for procarbazine (log rank p = &lt; 0.01 to 0.03).</p><p><em>Recurrent anaplastic astrocytoma</em></p><p>In a multicentre, prospective phase II trial evaluating the safety and efficacy of oral Lagona in the treatment of patients with anaplastic astrocytoma at first relapse, the 6 month PFS was 46 %. The median PFS was 5.4 months. Median overall survival was 14.6 months. Response rate, based on the central reviewer assessment, was 35 % (13 CR and 43 PR) for the intent-to-treat population (ITT) n=162. In 43 patients stable disease was reported. The 6-month event-free survival for the ITT population was 44 % with a median event-free survival of 4.6 months, which was similar to the results for the progression-free survival. For the eligible histology population, the efficacy results were similar. Achieving a radiological objective response or maintaining progression-free status was strongly associated with maintained or improved quality of life.</p><p><u>Paediatric population</u></p><p>Oral Lagona has been studied in paediatric patients (age 3-18 years) with recurrent brainstem glioma or recurrent high grade astrocytoma, in a regimen administered daily for 5 days every 28 days. Tolerance to Lagona is similar to adults.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Lagona is spontaneously hydrolyzed at physiologic pH primarily to the active species, 3-methyl-(triazen-1-yl) imidazole-4-carboxamide (MTIC). MTIC is spontaneously hydrolyzed to 5-amino-imidazole-4-carboxamide (AIC), a known intermediate in purine and nucleic acid biosynthesis, and to methylhydrazine, which is believed to be the active alkylating species. The cytotoxicity of MTIC is thought to be primarily due to alkylation of DNA mainly at the O<sup>6&nbsp;</sup>and N<sup>7&nbsp;</sup>positions of guanine. Relative to the AUC of Lagona, the exposure to MTIC and AIC is ~ 2.4 % and 23 %, respectively.&nbsp;<em>In vivo</em>, the t<sub>1/2</sub>&nbsp;of MTIC was similar to that of Lagona, 1.8 hr.</p><p><u>Absorption</u></p><p>After oral administration to adult patients, Lagona is absorbed rapidly, with peak concentrations reached as early as 20 minutes post-administration (mean time between 0.5 and 1.5 hours). After oral administration of&nbsp;<sup>14</sup>C-labelled Lagona, mean faecal excretion of&nbsp;<sup>14</sup>C over 7 days post-dose was 0.8 % indicating complete absorption.</p><p><u>Distribution</u></p><p>Lagona demonstrates low protein binding (10 % to 20 %), and thus it is not expected to interact with highly protein-bound substances.</p><p>PET studies in humans and preclinical data suggest that Lagona crosses the blood-brain barrier rapidly and is present in the CSF. CSF penetration was confirmed in one patient; CSF exposure based on AUC of Lagona was approximately 30 % of that in plasma, which is consistent with animal data.</p><p><u>Elimination</u></p><p>The half-life (t<sub>1/2</sub>) in plasma is approximately 1.8 hours. The major route of&nbsp;<sup>14</sup>C elimination is renal. Following oral administration, approximately 5 % to 10 % of the dose is recovered unchanged in the urine over 24 hours, and the remainder excreted as temozolomide acid, 5-aminoimidazole-4-carboxamide (AIC) or unidentified polar metabolites.</p><p>Plasma concentrations increase in a dose-related manner. Plasma clearance, volume of distribution and half-life are independent of dose.</p><p><u>Special populations</u></p><p>Analysis of population-based pharmacokinetics of Lagona revealed that plasma Lagona clearance was independent of age, renal function or tobacco use. In a separate pharmacokinetic study, plasma pharmacokinetic profiles in patients with mild to moderate hepatic impairment were similar to those observed in patients with normal hepatic function.</p><p>Paediatric patients had a higher AUC than adult patients; however, the maximum tolerated dose (MTD) was 1,000 mg/m<sup>2</sup>per cycle both in children and in adults.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Single-cycle (5-day dosing, 23 days non-treatment), 3- and 6-cycle toxicity studies were conducted in rats and dogs. The primary targets of toxicity included the bone marrow, lymphoreticular system, testes, the gastrointestinal tract and, at higher doses, which were lethal to 60 % to 100 % of rats and dogs tested, degeneration of the retina occurred. Most of the toxicity showed evidence of reversibility, except for adverse events on the male reproductive system and retinal degeneration. However, because the doses implicated in retinal degeneration were in the lethal dose range, and no comparable effect has been observed in clinical studies, this finding was not considered to have clinical relevance.</p><p>Lagona is an embryotoxic, teratogenic and genotoxic alkylating agent. Lagona is more toxic to the rat and dog than to humans, and the clinical dose approximates the minimum lethal dose in rats and dogs. Dose-related reductions in leukocytes and platelets appear to be sensitive indicators of toxicity. A variety of neoplasms, including mammary carcinomas, keratocanthoma of the skin and basal cell adenoma were observed in the 6-cycle rat study while no tumours or pre-neoplastic changes were evident in dog studies. Rats appear to be particularly sensitive to oncogenic effects of LAGONA, with the occurrence of first tumours within 3 months of initiating dosing. This latency period is very short even for an alkylating agent.</p><p>Results of the Ames/salmonella and Human Peripheral Blood Lymphocyte (HPBL) chromosome aberration tests showed a positive mutagenicity response.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Capsule content</u>:</p><p>Lactose Anhydrous,</p><p>Colloidal silicon dioxide,</p><p>Sodium Starch Glycollate (Type A),</p><p>Tartaric Acid,</p><p>Stearic Acid,</p><p><u>Capsule shell</u>, Size 0:</p><p>Lagona 5 mg hard capsules: gelatin, titanium dioxide (E 171). Yellow iron oxide (E 172), red iron oxide (E 172).</p><p>Lagona 20 mg hard capsules: gelatin, titanium dioxide (E 171), red iron oxide (E 172), yellow iron oxide (E 172).</p><p>Lagona 100 mg hard capsules: gelatin, titanium dioxide (E 171), indigotine FD&amp;C blue2 (E 132).</p><p>Lagona 140 mg hard capsules: Gelatin, titanium dioxide (E 171), indigotine FD&amp;C blue 2 (E 132).</p><p>Lagona 180 mg hard capsules: Gelatin, titanium dioxide (E 171), yellow iron oxide (E 172), red iron oxide (E 172), black iron oxide (E 172).</p><p>Lagona 250 mg hard capsules: gelatin, titanium dioxide (E 171).</p><p>&nbsp;</p><p><u>Printing ink</u></p><p>Shellac, dehydrated alcohol, Isopropyl alcohol, Butyl alcohol, propylene glycol, purified water, sodium ammonia solution, potassium hydroxide, black iron oxide (E 172).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                3 years
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Bottle presentation</u></p><p>Store below 30 &deg;C.</p><p>Store in the original bottle in order to protect from moisture.</p><p>Keep the bottle tightly closed.</p><p><u>Sachet presentation</u></p><p>Store below 30 &deg;C.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>HDPE Bottle presentation:</u></p><p>White opaque High Density Polyethylene Bottles with Polypropylene push lock assembly closure, with polyester coil containing 5 capsules.</p><p><u>Sachet presentation</u></p><p>Sachets composed of paper on linear low density polyethylene (outermost layer), aluminium and ethylene acrylic acid co-polymer (innermost layer).</p><p>Each sachet contains 1 hard capsule and is dispensed in a cardboard carton.</p><p>The carton contains 5 or 20 hard capsules, individually sealed in sachets.</p><p>Not all pack sizes may be marketed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Capsules should not be opened. If a capsule becomes damaged, contact of the powder contents with skin or mucous membrane must be avoided. If Lagona comes into contact with skin or mucosa, it should be washed immediately and thoroughly with soap and water.</p><p>Patients should be advised to keep capsules out of the sight and reach of children, preferably in a locked cupboard. Accidental ingestion can be lethal for children.</p><p>Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Manufactured by: EirGen Pharma Ltd.
For: SPIMACO
AlQassim pharmaceutical plant
Saudi Pharmaceutical Industries &
Medical Appliance Corporation.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                November  2017.
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>